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ABSTRACT 
Recent Canadian surveys report that many asthmatic children continue to 
experience uncontrolled asthma. The literature inforrns us that the lack of 
adherence to the guidelines from the Canadian Asthma Consensus regarding the 
use of inhaled corticosteroids (lCS) may be one of the obstacles faced by children 
living with this disease. The primary objectives of this study are to describe the 
use of lCS, including both the prescribing patterns and patient adherence iJsi~g a 
new adherence measure which allows estimating the relative proportion 
attributable to the physicians and patients. 
A cohort of 2,355 children aged 5-15 years with asthma and having had used 
more than 3 doses of inhaled short-acting ~2-agonists (SABA) per week on 
average during a 12-month period prior to tre"atment initiation with lCS was 
reconstructed using Quebec administrative health databases, between 1997 and 
2005. The new adherence measure was defined as the total days' supply dispensed 
to the. total days' supply prescribed. 
During the 12-month follow-upperiod, 20% of the· children received only 1 
prescription of lCS with no prescribed renewals. The median numberof 
prescriptions (inclùding prescribed renewals) was 4 corresponding to only 120 
days' supply prescribed. The median percent physician and patient adherence to 
the prescribed therapy were 32.9% and 58.6%, respectively. The proportion of the 
non adherence value attributable to the lack of prescribing daily long terrn therapy 
was 51.2%. 
A large percentage of children with persistent asthma were not prescribed lCS for 
chronic daily use and patient adherence was suboptimal. 
Keywords: asthma,. paediatric, children, inhaled corticosteroids, prescribing 
patterns, adherence 
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RÉSUMÉ 
Les résultats de récents sondages nous ont démontrés que l'asthme demeure mal 
. maîtrisé chez les patients asthmatiques canadiens. Selon la littérature, le non 
respect des lignes directrices du consensus canadiens sur l'asthme quant à 
l'utilisation des corticostéroïdes en inhalation (CSI) est potentiellement un 
obstacle dans la prise en charge de cette maladie. Les objectifs principaux de cette 
étude sont d'évaluer les profils d'adhésion des médecins ainsi que des patients 
quant à l'utilisation des CS! en utilisant. une nouvelle mesure d'adhésion nous 
permettant de déterminer la proportion relative attribuable à chacun. 
Une cohorte de 2 355 .enfants âgés asthmatiques de 5 à 15 ans et ayant utilisé en 
moyenne plus de 3 doses hebdomadaires de bronchodilatateurs à courte action 
(BCA) durant l'année précédant l'initiation au traitement des CS! a été 
reconstruite à partir de données extraites des banques de données administratives 
en santé du Québec, entre 1997 et 2005. La nouvelle mesure d'adhésion 
représente le nombre de jours de prescriptions reçues divisé par le nombre de jours 
de traitement prescrit. 
Durant le SUIVI de 12 mOlS de l'étude, 20% des enfants n'ont reçu qu'une 
ordonnance d'un CS!. Le nombre médian d'ordonnance (incluant le 
renouvellement autorisé d'une ordonnance) reçu était de 4.0 correspondant à 120.0 
jours de traitement prescrit. L'adhésion médiane des médecins et des enfants au 
traitement était de 32.9% et de 58.6%, respectivement. La proportion de non 
adhésion attribuable au manque de traitement prescrit à long terme était de 51.2%. 
La majorité des enfants n'ont pas reçu un traitement quotidien de CSI et l'adhésion 
du traitement de ces patients était sous-optimale. 
Mots-clés: asthme, pédiatrie, enfants, corticostéroïdes en inhalation, ordonnance, 
observance 
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PREFACE 
This MSc thesis consists of six chapters including an introduction, a review of the 
literature, a methodology and results sections, the manuscript of an article 
submitted for publication in a scientific journal and a discussion section. These 
chapters are followed by an overall conclusion, a bibliography and appendices. 
The introduction provides the rationale and objectives of the study presented 
herein. This chapter is followed by a review of the literature covering different 
aspects relevant to this project with an emphasis on findings pertaining to children 
5 years and older wh en available. The methodology and discussion chapters 
encompass the information found under the 'Methods' and 'Discussion' sections 
of the manuscript more comprehensively while the chapters on results and 
appendices present findings not reported in the manuscript. The article reports the 
results on the 'use of inhaled corticosteroids in children with persistent asthma. 
The overall conclusion provides a 'brief summary of the results of the study 
together with a few proposais for future research interest. The bibliography covers 
all articles cited in. the thesis; however, the manuscript includes its own 
bibliography. 
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CHAPTER 1: INTRODUCTION 
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Asthma is a chronic respiratory disease characterized by airway inflammation and 
acute symptomatic episodesof varying bronchial constriction. Clinical symptoms 
consistent with asthma include episodic or constant wheezing, chest tightness, 
dyspnea and cough. It is one of the most common chronic conditions in childhood 
and affects approximately 15.6% ofchildren aged 4to Il years and 11.7% aged 12 
to 19 years in Canada. (1) 
The goal of phamlacological therapy, as advocated by the widely distributed 
treatment guidelines including the Canadian Asthma Consensus (CAC) guidelines, 
is to achieve and maintain long-term control of asthma symptoms with the use of 
inhaled corticosteroids (lCS) as a first-line therapy for the initial treatment of 
persistent asthma, such that no more than three. doses of short-acting ~z-agonists 
(SABA) per week are required as rescue medication, excluding one additional 
daily dose per day for exercise-induced bronchoconstriction. (2;3) Regular use of 
lCS has been shown to reduce the impact of asthma on morbidity. (4-6) Despite 
the beneficial effect of lCS, Canadian surveys continue to show a significant gap 
between treatment goals and levels of asthma control.(7;8) As a result, patients 
continue to experience poor asthma control and thus, require emergency care.(l ;9) 
A major barrier for the optimization of pharmacological outcomes identified in the 
literature is the suboptimal use of lCS. Rates of non adherence among asthmatic 
patients have been reported to range from 32% to 50% through the use of. 
electronic monitoring devices suggesting that inappropriate use of lCS therapy 
remains a problem for a majority of patients. (10-12) 
Based on this information, the objective of an initial research project which has lèd 
to the study presented herein was to evaluate the impact of lCS therapy non-
adherence on the occurrence of moderate to severe asthma exacerbations in 
asthmatic children. Further methodological attempts to evaluate this relationship 
using various subpopulations, and different adherence measures and regression 
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models, it was found that the beneficial effect of adherence to lCS on 
exacerbations was very difficult to demonstrate using observational data due to the 
ove raIl suboptimal use of lCS and the strong presence of an indication bias (i.e., 
lCS was more likely to be used in patients with more severe asthma who, in turn, 
have a greater probability ofhaving an exacerbation). 
It remained unclear from the data obtained in the initial research projed whether 
the suboptimal use of lCS was attributabie to physicians' non adherence to 
treatment guidelines for the prescription of lCS as maintenance therapy or 
patients' non adherence to their prescribed regimen. 
Although patients' non adherence to their prescribed lCS therapy is weIl 
documented, there is less evidence on the prescribing patterns arnong physicians. 
Surveys conducted in the United States (US.) in 1999 and 2004 found that only 
half of the primarycare physicians reported adherence to guideline 
recommendations for the prescription of daily lCS for children with persistent 
asthma.(l3; 14) Recently, a Canadian study surveying primary care physicians 
found that 20% of uncontrolled patients used SABA alone and the most frequently 
reported recommended change for these patients was the initiation of lCS, but in 
only 52% ofthem.(15) 
To our knowledge, there are no studies US1l1g administrative data that have 
simultaneously assessed the prescribing patterns of lCS and the adherence to this 
medication. Using administrative claims data from the province of Québec 
(Canada), the primary objectives of the study presented herein were to describe the 
use of lCS in children with persistent asthma, including both prescribing patterns 
and patient adherence to prescribed lCS therapy using a new adherence measure. 
A secondary objective of the study was to describe markers ofuncontrolled asthma 
as a function of the use ofICS. 
CHAPTER 2: REVIEW OF THE LITERATURE 
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2.1 Prevalence and economic burden 
Asthma, a chronic inflammatory disease of the airways, is a 'major public health 
concem. It is one of the most common chronic diseases in the world and, in 2003, 
it was estimated that as many as 300 million people in the world suffer from 
asthma. (16) 
The prevalence of diagnosed asthma in the United States (U.S.) and Canada is 
amongst the highest in the world for both children and adults. (16) In 2005, the 
National Center for Health Statistics estimated 7.7% of people had asthma in the 
U.S. Prevalence rates were highest among children aged 5 to 17 years; 9.9% of 
.. 
children aged 5 to Il years and 9.6% of children aged 12 to 17 years compared to 
7.2% of adults. (17) Asthma is the niost common chronic respiratory dise?-se in 
Canada, accounting for approximately 80% of the respiratory disease and 
affecting, in 2007, approximately 8.0 % and 8.1 % of the population aged 12 years 
or older in Canada and Québec, respectively. (18; 19) Consistent with the U.S. 
data, asthma prevalence rates are highest in children. In 2007, the prevalence of 
asthma among children 12 to 19 years of age was approxirriately 1l.5% in Canada 
and 9.9% in Québec. (18) According to the 2000/01 National Population Health 
Survey, asthma prevalence among children 0 to Il years of age reached 13.4% and 
15.1 % in Canada and Quebec, respectively. (9) 
Asthma continues to be a major cause of hospitalization for children in Canada. In 
2004, asthma contributed to 10% and 8% of aIl hospital admissions in the 0-4 
years and 5-14 years age groups, respectively. (1) In 1999/2000, asthma was the 
leading cause of hospitalizations among children aged 1 to 9 years and accounted 
for one quarter of the 78,221 hospitalizations due to respirat?ry diseases among 
children and youth under 15 years. (20) 
The economic burden of asthma is considerable in North America. (16) The 
Canadian average annual direct costs of asthma, inc1uding hospital, physician and 
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medications, were reported to be 705.4 million dollars in 2000. (1) In 1995, the 
annual direct co st of asthma per children over the age of 4 years was estimated to 
be $663 from the Ontario Minister of Health perspective which excludes 
medication costs. The largest cost component was hospital admissions, accounting 
for 77% of the total costs. The medication costs and dispensing fees from 'the 
combined societal and patient perspectives were estimated to be $446 per year. 
(21) 
Üsing US. data from the 1987 Medical Expenditure Survey, Lozano and 
colleagues estimated that children with asthma incurred an average of 2.8 fold 
increase in total health care expenditures, including prescriptions, ambulatory 
visits, emergency department visits and hospitalizations, compared with children 
without asthrna. (22) Further analysis of the 1987 data showed that the largest 
proportion of costs was due to hospitalizations followed by prescriptions and 
emergency department visits. (23) 
Asthma is an increasingly common chronic disorder. It is a leading cause of 
hospitalization in children and brings significant direct costs to societies. The data 
on hospitalization suggest that many individuals with asthma continue to have 
inadequate control of their disease. (1) 
2.2 Diagnosis and management of asthma in children 
Asthma is a chronic respiratory disease characterized by airway inflammation and 
acute symptomatic episodes of varying bronchial constriction. The diagnosis of 
asthma as suggested by both the Canadiari Asthma Consensus guidelines (CAC) 
and the Global Initiative for Asthma (GINA) guidelines for children over 5 or 6 
, years of age is mainly based on family history, the reported symptoms, physical 
examination as weIl as the measurements of lung function and allergie status. (2;3) 
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Clinical symptoms consistent with asthma include episodic or constant wheezing, 
chest tightness, dyspnea and cough. Symptoms can be provoked by allergic or 
nonallergic environmentalstimuli such as after exposure to specific irritants, cold 
air or by seasonal changes. Nocturnal occurrence is common. Symptoms can be 
acute, also known as exacerbations of asthma or asthma attacks, which are 
characterized by episodes of increase in patient's symptoms, such as shortness of 
breath, cough, wheezing and/or ch-est tightness or chronic. The patterns of asthma 
symptoms are variable and non-specific, especially in children which may more 
easily result in misdiagnosis (e.g. wheezy bronchitis). Alternative conditions 
which can also cause wheezing such as upper respiratory tract infections, 
pneumoma, gastroesophageal reflux or cystic fibrosis must be considered and 
excluded. (2;3) 
Measurement of allergic status is warranted especially because of the strong 
association between asthma and allergic rhinitis. Skin testing or measurement of 
specific IgE in serum can help identify risk factors that cause asthma ih sorne 
patients. (2;3) 
Objective measurements of lung function, and particularly the demonstration of 
reversibility of lung function abnormalities, are highly recommended for children 
over the age of 5 or 6 yèars to help corifirm the diagnosis and to assess its severity. 
(2;3) This is especially important as diagnosis based on,the presence of symptoms 
alone maybe inaccurate as asthma patients, including caregivers, generally 
underestimate current discomfort. (2;24) Measurements of lung function are not 
reliable in younger children as they may have difficulty in performing 
reproducible results. 
Once diagnostic has been made, a stepwise approach is used for therapy decisions 
based on asthma severity. Two different approaches have been proposed to assess 
asthma severity. The CAC guidelines advocate assessing severity once treatment 
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has been initiated and incorporates the level of treatment needed to achieve control 
in their assessment while the GINA guidelines advocate assessing severity based 
on the underlying disease of the subjects on initial presentation. (2;3) 
As a result of the two different approaches, the CAC guidelines recommend initial 
treatment based on asthma control while the GINA guidelines recommend initial 
treatmentbased on the degree of asthma severity to achieve asthma control. 
Although different, they both use similar clinical features in their assessment as 
shown in the following two tables. These clinical features include respiratory 
symptoms, lung function abnormalities, limitations of activities and need for 
reliever treatment. Once treatment has been initiated, both guidelines involve the 
responsiveness to treatment to form the basis for ongoing treatmentdecisions. The 
responsiveness refers to the degree of clinical control achieved by therapy. The 
criteria for determining whether asthma is controlled depend on the frequency or 
value of the clinical features as described in the following table. (2;3) 
Indicators of controlled asthma 
Frequency or value 
Characteristics Goals of CAC guidelines Goals of GINA guidelines 
Daytime symptoms < 4 days/week Twice or less/week 
Nocturnal symptoms/awakenings < 1 night/week None 
Limitations of activities None None 
Exacerbations Mild, infrequent None 
Need for reliever/rescue treatment < 4 doses/week 1 Twice or less/week 
Lung function (FEY 1 or PEF)L,t > 90% of personal best Normal or near normal 
Absence from work or school None --
PEF diurnal variationJ,t < 10-15% --
1 May use 1 dose/day for preventIOn of exerclse-mduced symptoms 
2 FEY 1 denotes the forced expiratory volume in 1 second and PEFdenotes the peak 
expiratory flüw 
3 Diurnal variation is calculated by subtracting the lowest PEF from the highest 
and dividing by the highest PEF multiplied by 100 for morning and night over a 2-
week period. 
1 lung function is not reliable for children below the age of 5 or 6 years 
Source: CAC guidelines 2004 and GINA guidelines 2007 
r 
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In addition to guiding clinicians in initial treatmentdecisions, the GINA 
classification of severity also serves as a basis for the selection of subjects in 
clinical trials as' cited under subsection 2.3.1. There are four categories: 
intermittent, mi Id persistent, moderate persistent or severe persistent. The 
characteristics of each category are provided in the following table. 
Classification of Asthma Severity by Clinical Features Before Treatment 
Intermittent 
Symptoms less than once a week 
Brief exacerbations 
Noctumal symptoms not more than twice a month 
FEY 1 or PEF 2: 80% predicted 
FEY 1 or PEF variability < 20% 
Mild Persistent 
Symptoms more than once a week but less than once a day 
Exacerbations may affect activity and sleep 
Noctumal symptoms more than twice a month 
FEY, or PEF 2: 80% predicted 
FEY, or PEF variability < 20 - 30% 
Moderate Persistent 
Symptoms daily 
Exacerbations may affect activity and sleep 
Noctumal symptoms more than once a week 
Daily use of short-acting ~z-agonists 
FEY 1 or PEF 60 - 80% predicted 
FEY 1 or PEF variability > 30% 
Severe Persistent 
Symptoms daily 
Frequent exacerbations 
Frequent iloctumal asthma symptoms 
Limitation of physical activities 
FEY 1 or PEF :s 60% predicted 
FEY 1 or PEF variability > 30% 
Source: GINA 2007 
This classification do es not take treatment exposure into account and is therefore 
most appropriately used for patients who are cohtroller therapy naïve. (2) This 
classification is very similar to the classification' used by the 2002 National 
Asthma Educ,ation and Prevention Pro gram (NAEPP) coordinated by the U.S. 
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National Heart, Lung, and Blood Institute of the National Institutes of Health 
which is also cited in this review. (25) 
Despite widely available treatment guidelines, the evaluation of the patients' 
disease course remains suboptimal. Challenges in assessing asthma control may in 
part be due to the varying feature of an individual patient's asthma and the 
frequency and rapidity an individual patient's feature change over time. (26;27) 
These challenges appear to be more so in children than for adults according to 
Chipps and colleagues who found, over a 12-week period, that controller therapy , 
naïve pediatric subjects spent, on average, 27%, 18%, 48% and 8% of weeks 
meeting aIl criteria of the NAEPP, for intermittent, mild, moderate or severe 
persistent asthma, respectively. (26) Unless periodic assessment of asthma control 
is conducted to optimize the value of treatment, as recommended by treatment 
guidelines, 'underestimation of asthma severity may be likdy contributing to 
inadequate therapy, and ultimately to asthma morbidity and mortality. (2;3;26) 
Although there is no cure for asthma, effective clinical management can reduce the 
impact of asthma on morbidity, and decrease the economic burden associated with 
asthma-related emergency department and hospitalizations visits. Interventions 
that. can help asthma becontrolled include taking adequate asthma controller 
therapy, avoiding contact with environmental "triggers" such as tobacco smoke, 
indoor allergens such as dust and fungi, outdoor allergens such as pollens, treating 
conditions associated with asthma such as upper respiratory tract infections, and 
receiving regular monitoring from health-care professionals. (2;3) 
2.3 Pharmacological management 
The goal of pharmacological management is to achieve and maintain clinical 
control. There are two main categories of pharmacological therapy, namely 
ccintrollers and relievers. In children, controllers include inhaled corticosteroids, 
leukotrienes modifiers, long-acting ~2-agonists and anti-allergic agents such as 
Il 
cromoglycate and nedocromil. . These agents are considered preventive therapy 
and are usually taken daily on a long-term basis to keep asthma under control, 
mainly through their anti-inflammatory effects. The most effective ofthese agents 
. are the inhaled corticosteroids (leS) and are currently the recommended first-line 
controller therapy for children of ail ages. (2;3) Relievers are best represented by 
the short-acting ~2-agonists (SABA), which are very effective for acute relief of 
, , 
syrnptoms, but their frequent use is associated with a heightened future risk of 
severe asthma attacks. (2;3;28~30) 
It is recommended that low-dose leS be introduced as initial maintenance therapy 
even if patients present fewer than 3 syrnptoms per wet?k. (3) For childreri not 
sufficiently controlled with a low-dose of leS, an alternative to increasing the leS 
dose is the addition of long-acting ~2-agonists (LABA) or leukotrienes modifiers 
(LTRA) although evidence of effectiveness of combination therapy is not as weil 
established in younger children. The use of oral corticosteroids (OeS) is 
recommended for the treatment of acute severe exacerbations. (2;3) 
It has been weil demonstrated from clinical trials that r~gular use of leS is 
associated with improvements in syrnptoms and lung function. (31-33) More 
recent clinical trials and observational studies have also shown the beneficial 
effect of leS on severe asthma-related events such as exacerbations among 
patients with various degree of asthma severity. A few of these studies conducted 
in children or in .population including children with mild to more severe asthma 
are discussed below. 
2.3,1 Evidence of efficacy of inhaled corticosteroids in children from randomized 
clinical trials 
The lnhaled Steroid Treatment as Regular Therapy in Early Asthma (START) 
study conducted in patients 5 to 66 years of age with new-onset mild persistent 
asthma, based on the GINA criteria for syrnptoms and lung function abnormalities, 
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reported that early use of low-dose lCS was associated with a significant 44% 
reduction i~ Severe exacerbations (HR 0.56,95% CI 0.45 to 0.71, p<O.OOOl) over 
a period of 3 years. (34) A separate analysis was conducted in a subgroup of 
patients, those < Il years of age, to evaluate whether ICS was associated with the 
risk of a severeasthma-related event (SARE), as defined by an event requiring an 
unscheduled admission to hospital or emergency treatment, or which resulted in 
death due to asthma, over the 3 years. It was found that the low-dose ICS group 
relative to usual care (placebo) was associated with a significantly reduced risk of 
SARE (HR 0.60, 95% CI 0.40 to 0.90, p=0.012). (35) The Optimal Treatm,ent for 
Mild Asthma (OPTIMA) study, conducted in patients 2: 12 years of age with mild 
persistent asthma based on the GINA criteria for symptoms and lung function 
abnormalities, showed a 60% reduction in the risk for the first severe asthma 
exacerbation (RR 0.40, 95% CI 0.27 to 0.59) in treatment-naïve patients receiving 
low-dose ICS compared to patients receiving placebo and a 19% reduction (RR 
0.81,.95% CI 0.65 to 1.01) in treatment-experienced patients receiving high-dose 
ICS compared t6 patients receiving low-dose ICS. (36) 
Daily low-dose ICS has also been compared with intermittent 'as needed' 
treatment with tcs in two small studies, one of which was conducted in children. 
The Helsinki Early Intervention Childhood Asthma (HEICA) study compared the 
effect of continuo us and intermittent 'as needed' ICS treatments following 6 
month of continuous ICS therapy in patients 5 to 10 years of age. According to 
symptoms and lung function tests, the majority of patients met the GINA criteria 
for mild persistent asthma. Over a one year period, the mean number of 
exacerbations was significantly lower for patients receiving continuous ICS 
treatment (0.97) compared with patients receiving intermittent ICS treatment 
(1.69). (37) The HEICA study followed the Improving Asthma Control Trial 
(IMPACT) conducted in patients 18 to 65 years of age following a 10 to 14 days 
of intense combined therapy (OCS and ICS). With the exception of accepting a 
baseline FEY 1 as low as 70% of the predicted value, patients met the GINA 
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criteria for mild persistent asthma. This study showed similar rates of asthma 
exacerbations between daily use of lCS and intermittent short-course use of lCS or 
OCS, together with an action plan, over a one year period. However, the authors 
conclude that larger studies, conducted for a longer period of time, are needed to 
examine the clinical benefits of an intermittent symptom-based therapy. (38) 
The Childhood Asthma Management Program (CAlVIP) was conducted in patients 
5 to 12 years of age with mild to moderate persistent asthma, as defined by the 
presence of symptoms or by the use of SABA more than twice weekly or by the 
use of daily asthma medication and a concentration of 12.5 mg or less of 
methacholine causing a 20% fall in FEY 1. 'This study also found beneficial effect 
of medium-dose lCS monotherapy, as indicated by 43% lower rate· of 
hospitalization (p=0.04), a 45% lower rate of urgent care visits (p<O.OOl), and a 
43% lower rate of courses of prednisone treatment (p<O.OOl) relative to the 
placebo group over a four to six-year period. (39) 
There are few studies conducted in children which have evaluated and compared 
different therapy strategies for those needing a step up in their asthma treatment 
(e.g. an increased in dose ofICS and/or the addition of a second controller therapy, 
such as a LABA or a LTRA) in order to achieve asthma control. 
Evidence for effectiveness of the addition of LABA controller therapy to lCS in 
patients below the age of 12 with uncontrolled asthma on symptoms control and 
particularly on exacerbations is not weIl established. (2;3) Findings of a 
systematic review of eight randomized controlled trials of add-on LABA therapy 
in patients ranging in age from 4 to 17 years showed a lack of evidence for the 
control of asthma exacerbations in children. (40) However, more recently, a'study 
conducted in children aged 4 to Il years has {ound that fixed dose combination 
therapy for maintenance plus additional doses for as-needed symptom relief 
reduces rates of asthma exacerbation by 70 to 79% compared to fixed dose 
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combination therapy alone or high dose lCS. (41) The Gaining Optimal Asthrha 
Control (GOAL) study conducted in patients:::: 12 years of age has shown that the 
longitudini:t1 effect of the ICS/LABA combination therapy in achieving guideline-
defined asthma control was significantly greater compared to ICS monotherapy 
and the mean annual rates of exacerbations were significantly lower for the 
combination therapy. (42) 
There is little evidence to date for effectiveness of the combined ICS and LTRA 
therapy in children as a substitute to increasing the dose of lCS. (2;3) Add-on 
L TRA treatment to children aged 6 to 14 years with persistent asthrna reduced the 
mean percentage exacerbation days significantly compared to those receiving ICS 
alone. (43) More recently, a study conduc~ed in children aged 6 to 14 years with 
moderate persistent asthma found that the overall control of asthma with the 
combined LTRA and low. dose ICS therapy was inferior to that of high dose lCS. 
(44) 
Treatment remains problematic for a minority of patients with severe, difficult-to-
treat asthma. The natural history of asthrna severity is poorly understood in this 
cohort of severe, difficult-to-treat asthrnatic patients. (45-47) High dose of 
corticosteroids remain the most effective therapy for most patients. (2) 
Overview ofsafetv [rom randomized clinical trials 
The long-terrn safety of low to medium dose ICS has been weil established. 
(48;49) However, both the START and the CAMP trials showedevidence of a 
small decline in height velocity during treatment of ICS (1.1 to 1.34 cm 6ver 3 to 6 
year period). (34;39) The decline in the rate of growth was greatestin the first year 
of treatment. The CAMP study suggests that the projected adult height, by bone 
age deterrninations, to be similar to the placebo group. (39) This finding· 
corroborates those of a separate study, which found that after a 10-year follow-up 
period (mean 9.2 years), the budesonide-treated chi1dren, at a mean daily dose of 
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412 flg, attained adult height. (50) Furthermore, in previous study conducted in 
the same chi1dren population, the authors reported no correlation between bone 
minerai density, bone minerai capacity, bone calcium and body composition and 
the duration of treatment or dose (averaged daily dose Of budesonide was 504 flg) 
after 3 to 6 years of treatment. (51) Patients requiring higher dose les should be 
monitored for adverse effects. (3;49) 
. 2.3.2 Evidence of ejJectiveness of inhaled corticosteroids from observational 
studies 
Although evidence of clinical effectiveness based on observational studies is not 
easy to demonstrate, in part due to the fact that les is more likely to be prescribed 
for patients with more severe disease and who are at greater risk of having an 
exacerbation, the effectiveness of les on reducing the risk of first hospitalization, 
hospital readmissions or death due to asthma has been shown. A few recently 
published studies are discussed below. 
ln a case-control study of newly treated asthmatics between 5 and 44 years of age, 
it was found that regular users of les were 40% less likely to be hospitalized for 
asthma compared to theophylline regular users (OR 0.6; 95% CI 0.4 to 1.0) during 
the first 12 months of treatment. Regular use was defined as the dispensing of at 
least 1 prescription every 3· months. Both treatments had been initiated within the 
year of the recognition of asthma. (4) 
Similarly, early initiation of les following hospitalization for asthma also reduces 
the risk of a readmission for asthma. Based on a large cohort of 1 year duration in 
newly treated asthmatics between 5 and 54 years of age, it was found that subjects 
taking regular use of leS, for at least 16 days and as long as 6 months,following 
discharge of an initial hospitalization for asthma were 40% less likely to be 
readmitted for asthma than non les users (RR 0.6; 95% CI: 0.4-0.9). The author 
suggested that the lack of effect of les within the first 15 days of treatment Is 
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consistent with the mInImum length of time required to affect chronic 
inflammation while the fading of the effect ofICS over 6 month ofuse may be due 
to confounding as subjects using ICS regularly for 6 months or more may have 
more severe asthrna. (5) 
The effediveness of ICS over a longer period of time was subsequently evaluated 
using a case-control design withineach of two cohorts of newly treated asthmatics 
between 5 and 44 years of age. The first cohort consisted of all subjects from the 
initiation of their asthma treatment, while the second consisted of subjects 
hospitalized for asthma from the date of discharge. The mean duration of follow-
up was 10:8 and 7.6 years, for the first and second cohort, respectively. This study 
showed that regular use of ICS was associated with a 31 % reduction in the rate of . 
hospital admissions for asthma (OR 0.69; 95% CI 0.57 to 0.83) and 39% reduction 
in the rate ofhospital readmissions (OR 0.61; 95% CI 0.50 to 0.75). The rate of 
reduction found during the first 4 years of follow-up was sustained over the longer 
term. (6) 
In another three large retrospective studies of similar design, but using different 
source cohorts of which one was exciusively conducted in children, it was found 
that ICS was 'significantly associated with a decrease risk of a first hospitalization 
relative to patients with no ICS dispensing, after sirriultaneous adjustment for 
markers of disease severity (rate ratio ranged from 0.4 to 0.8). The ICS-associated 
protection was most pronounced among high-SABA users. In these studies, ICS 
drug use was measured by dispensing rates, which was .the number of canisters 
dispensed over the duration of follow-up in two studies or based on the quantity 
and strength of drug dispensed over the duration of follow-up in one study. The 
duration offollow-up for t~ese studies was between 1 to 10 years. (52-54) 
To evaluate whether and to what extent the use of ICS prevents death from 
. asthma, a case-control study of newly treated asthrnatics between5 and 44 years of 
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age was conducted over a period of 6 years. Findings from a continuous dose-
response analysis showed that the rate of death among users of ICS decreased by 
21% (RR 0.71; 95% CI 0.65 to 0.97) for every additional canister of leS used. 
during the year and by 54% (RR 0.46; 95% CI 0.26 to 0.79) for every additional 
canister of ICS used during the previous six months. AIso, the rate of death during 
the first 3 months following ICS discontinuation was significantly higher than the 
rate among those who continued to use ICS (RR 4.6; 95% CI 1.1 to 19.1). (55) 
Overall, the findings from both randomized clinical trials and observational studies 
support regular use of lCS therapy to reduce the risk for exacerbations and other 
severe asthma-related events. Regular use of ICS has been shown to reduce the 
risk ofhaving a severe exacerbation by 40%.to 45% amongchildren aged 12 years 
or younger and by 60% among older children and adults in clinical trials: 
Consistent with. these findings, observational studies have shown that regulqr use 
ofICS reduces the risk of asthma-related hospital admissions by 40% to 60% and 
hospital readmissions by 39%. ' Moreover, the rate, of death was reported to 
decrease by 54% for every additional canister of lCS used during the previous six 
months. As recommended by the treatment guidelines, once therapy has been 
initiated, effectiveness of ICS should be evaluated periodically and treatment 
should be stepped up or down in order to maintain asthma control and to minimize 
the risk of side effects. (2;3) 
2.4 Suboptimal control of asthma and underlying risk factors 
Despite widely available treatment guidelines and therapeutic advances aimed at 
preventi.ng ,onset of symptom and providing long-terrn control of asthma 
symptoms in children and adults, large surveys continue to show significant gap 
between treatment goals and levels of asthma control around the world. As a 
result, patients continue to have symptoms and lifestyle restrictions and to require 
emergency care. 
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The most recent major. Canadian survey, The Reality of Asthma Control (TRAC), 
conducted in 2004 reported that 53% of the 893 patients aged 18 to 54 years old 
,had symptomatic uncontrolled asthma defined as failing to meet two of the six 
symptom-based criteria for asthma control of the CAC guidelines (i.e., minimal 
daytime and night-time symptoms, no limitations on physical activity, mild and 
infrequent exacerbations, no absences from work ~r school, and fewer than 4 doses 
of SABA per .week). Patients with uncontrolled asthma required significantly 
more acute care visits (unscheduled physician visit, emergency department visit, or 
ovemight hospitalization) due to asthma exacerbations compared to patients with 
controlled asthma. The TRAC survey concluded that patients as weIl as physicians 
continue to fail to recognize the seriousness of acute asthma episodes leading to 
increase burden topatients and on the health care system. (56) 
The proportion of patients with uncontrolled asthma in TRAC is consistent with 
findings from a similar national survey conducted in 1999 in 1001 adults or 
parents of children aged 4 to 15 years where 57% of patients were found to have 
uncontrolled asthma (measured by the same criteria as in TRAC), indicatingthat 
little has changed over a period of 5 years. (8) 
Similarly in the U.S., the Children and Asthma in America (CAlA) survey, 
conducted in 2004 to assess knowledge, attitudes and behaviours toward asthma in 
801 children aged 4 to 18 years old, concluded that a significant number of 
children do not have asthma under controlaccording to the symptom-based criteria 
for asthma control of the NAEPP guidelines (similar to the GINA criteria) which 
include frequency and severity of symptoms, utilization of emergency care, missed 
work and/or school and use of SABA. Poorly controlled ast~a also caused a 
significant number of acute care visits (unscheduled physician visit, emergency 
department visit, or ovemight hospitalization) and to interfere with everyday lives 
of children and their families. (24) Furthermore, theoverall findings ofthis survey 
were similar to those of the previous Asthma in America (AlA) survey conducted 
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In 721 children «16 years) and 1788 adults In 1998, indicating that little has 
changed over a period of 6 years. (57) . 
The Asthma Insights and Reality (AIR) surveys conducted in 29 countries between 
1998 and 2001 to determine international variations in the severity, control, and 
management of asthma according to the <?INA criteria for asthma control in 3153 
children and 7786 adults also found that a significant proportion of patients 
continue to have symptoms and lifestyle restrictions andto require emergency 
care. (58) 
These surveys reveal that for a majority of patients, asthma control as defined by 
CUITent treatment guidelines is not being met. There are many aspects of asthma 
management that may be contributing to suboptimal asthma control. A few of 
these aspects which have been highlighted in the surveys are commented below. 
2.4. J Perception of asthma control 
It is recognized that sorne patients may not accurately perceive the limitations 
caused by their condition especially if their asthma is long-standing. (2;59) 
Unfortunately, poor perception of asthma control can have many implications in 
the management of asthma. Patients may not seek medical help for their asthma 
symptoms wh en they should. Physicians who often base their assessment of the 
patient's condition on symptoms reported by the patient may also underestimate 
asthma control and subsequently under prescribe preventive therapy. (60) 
Moreover, poor perception of asthma control is a major determinant of pediatric 
adherence to their prescribed pharmacological therapy. (61 ;62) Despite these 
implications, surveys indicate that poor perception of asthma control continues to 
be prevalent. 
Among patients who claimed their asthma was weil controlled in the TRAC 
survey, 45% believed that making 1 or 2 visits to an emergency department was an 
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expected part of their condition. (56) The Canadian survey conducted in 1999 
reported that among participants with uncontrolled asthma, 85% believed that their 
asthma was adequately or well controlled. (8) The CAlA survey indicated nearly 
80% of respondents believed their or their children's asthma was well controlled; 
however, fora significant number of these children, asthma was uncontrolled 
based on the frequency and severity of the reported symptoms. (24) The AIR 
surveys indicated that 32% to 49% of patients with severe symptoms and 39% to 
70% of patients' with moderate symptoms felt that their asthma was well 
controlled. (58) 
Poor perception of asthma control is not limited to children as indicated by the 
CAlA survey where caregivers represented 85% of the respondents. Furthermore, 
a communication gap within the family was found when responses between 
parents and children 10 and 15 years of age were compared. (24) Thesefindings 
are consistent with those from several other studies which have shown the 
discrepancy between the parents' perception of their children asthmacontrol and 
their children actual disease status. (63) 
2.4.2 Asthma management education 
It is agreed that patients must understand and accept their disease, the role of their 
therapy, the importance of adhering to prescribed therapy and avoid possible risk 
factors to gain asthma control and avoid exacerbations. (64-66) This is especially 
important given the variability of the disease and othe unpredictable nature of 
asthma attacks. (27) Yet, surveys suggest that many patients have insufficient 
asthma knowledge to self-manage their condition. 
The TRAC survey reported that 33% of the participants had not been taught to 
recognize the early signs of asthma worsening and 25% had not received 
instruction on what to do if their asthma symptoms worsened. Moreover, up to 
33% of patients could not make the distinction between controller and reliever 
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medications, and did not know how to use them. (56) Medication awareness was . 
. also po or among the participants of the Canadian survey conducted in 1999 and 
often resulted in inappropriate use of ICS (i.e., during asthma attacks or to prevent 
exercise-induced asthma). (8) In the CAlA survey, it was conc1uded that patients' 
lack of understanding about asthma risk factors, treatment and symptom 
prevention remained a major obstacle for the management of asthma. 
Two of these surveys have also indicated that the standards set forth by the 
treatment guidelines for ongoing monitoring, inc1uding follow-up healthcare visits, 
lung function testing and written action plans were not met. (8;24) These activities 
are integral components of asthma education. (2;3) 
2.4.3 Patterns of asthma medication ùse 
Lack of adoption to the pharmacological therapy recommendations of the 
treatment guidelines may also be one aspect contributing to suboptimal asthma 
control. Although these guidelines advocate the use ofICS as thefIrst-line therapy 
for the treatment of persistent asthma, underuse of ICS and Qveruse of SABA are 
still evident. 
The Canadian survey conducted in 1999 reported that 26% of the patients with 
uncontroUed asthrha were not using ICS and among those using ICS, only 64% 
were using ICS regularly. SABA was overuse.d by 37% of aU patients surveyed. 
(8) The CAlA survey conducted in 2004 found that 42% of patients surveyed 
overused SABA in the· previous month. (24) The AIR surveys also found that 
patients with persistent asthma had low use of controller therapy and high use of 
quick-relief inedication (data not shown). (58) This pattern of medication use 
cOIToborate with findings from the AIA conducted in 1998, reporting CUITent use 
of anti-inflammatory medications in only 26.2% ofpatie~ts with persistent asthma. 
ICS represented 72.5% of the anti-inflammatory medication. Of these patients, 
79.7% reported CUITent use of reliever medication. Inadequate pharmacological 
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management was more apparent in the younger age patients (adolescents, young 
adults and preschool age children) than adults over the age of 35 years. (67) 
Without a doubt, reasons for the widespread suboptimal asthma control reported 
by the recent ,surveys are most likely multi-factorial and beyond the aspects 
presented herein. Nevertheless, it is clear, from the surveys' findings that 
improvements in promoting the disease and the appropriate manageIT}ent of the 
disease are waITanted in helping patients meeting asthma control as defined by 
CUITent treatment guidelines. 
2.5 Prescfibing patterns of inhaled corticosteroids 
Physici<ins' adherence to treatment guideline recommendations for the prescription 
'of ICS as maintenance therapy is essential to the successful pharmacological 
management of asthma. A few of the studies which have examined the prescribing 
patterns of ICS and underlying factors which may affect the prescription of ICS 
are summarized below. 
Iwo large surveys evaluating factors that may affect prescribing habits conducted 
in the U.S. in 1999 and,2004 found that only half of the primary care physicians 
(paediatricians and family physicians) reported adherence to guideline 
recommendatioils for the prescription of daily ICS for childrenwith persistent 
asthma. Among other factors, physicians' non adherence to daily ICS prescription 
was significantly associated with lack of agreement with the guideline 
recommendations and the presence of external barriers (e.g. lack of reimbursement 
and parent· hesitancy regarding ICS). (13;14) In another large U.S. survey 
conducted in 1998 to describe asthma care for children, it was found that 47% of 
the primary care physicians reported 1 or more concerns regarding potential si de 
effects of corticosteroids and 20% were maintaining the most severe patients (with 
continuous symptoms) on the same dose ofICS. (68) 
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A US. retrospective cohort studyover a 5-yr period (1994-1998) exammmg 
prescribing patterns among prescribers specialty revealed that gener"alists and 
especially paediatric emergency department physicians and paediatricians were 
among the lowest proportions of prescribers ofICS. In 1998, prescriptions of lCS 
represented 24% of ail asthma medications for patients aged 5 to 45 years with 
moderate to high risk asthma, defined by those with ~ 3 outpatient visits, 2 
outpatient visits and > 3 asthma medication claims, ~ 1 emergency department 
visit or ~ 1 hospitalization prior to study entry, suggesting that many patients 
continued to be managed without lCS therapy. (69) 
Under recognition of uncontrolled asthina by physicians could also be a factor 
affec~ing prescribing behaviours. A recent Canadian study su[Veying primary care 
physicians and their patients ~ 12years found that physicians regarded 42% of 
their patients as havïng uncontrolled asthma while 59% of the patients reported not 
meeting one of the five symptoms based criteria bf the CAC (daytime symptoms, 
sleep disturbances, physical activities, absenteeism and use of SABA). An 
explanàtion provided by the survey findings for the under recognition of 
uncontrolled asthma was that physicians' assessment of asthma control was not 
concordant with guidelines assessment recommendations, particularly regarding 
the overuse of SABA. Physicians were more likely -to propose follow-up visits 
and to report plans to alter medication regimens for their patients with 
uncontrolled asthma. (15) 
These studies suggest that under prescription of lCS lS still very prevalent for 
patients with persistent asthma. 
2.6 Patient adherence to inhaled corticosteroids 
Patient non adhetence to their prescribed lCS therapy is also another obstacle to 
the successful pharmacological management of asthma. The effectiveness of lCS-
therapy can be greatly compromised in the presence of inadequate adherence. The 
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consequences of inadequate adherence include increased symptoms and asthma 
exacerbations, both of which can lead to increased morbidity and increased health 
care costs. 
2.6.1 Definition 
Adherence to a drug regimenmay be defined as the extent to which a patient's 
actual history of drug administration corresponds to the agreed upon prescribed 
regimen. (2;70;71) Studies presented in thissection have assessed adherence in 
terms of medication consumption or medication acquisition. Sorne of these studies 
use the term compliance iIi the same way as adherence. 
2.6.2 Adherence assessment 
A range of indirect methods with varying degree of validity and utility have been 
used to me as ure adherence in asthmatic patients. Sorne of these methods include 
canister weights, electronic devices attached to metered dose inhalers in order to 
record date and time of medication use, self-reports from patients or caregivers 
and pharmacy refill records. (l 0; 12;72~76) 
. Among the several different indirect methods measuring adherence, the electronic 
devices is currently considered the' gold standard' as they offer the most objective, 
reliable measurements. (77) A study comparing adherence assessment methods 
among asthmatic. patients found that electronic ,adherence was significantly more 
accurate than self-reports (mother and child) or canister weight measures. This 
study was conducted over a period of 6 month in 27 children 7 to 12 years of age 
with mild to moderate asthma and requiring daily use of lCS according to the 
frequency of asthma symptoms. The Doser-Clinical Trials version (Doser CT; 
Meditrac, Inc, Hudson, MA) was used for the electronic recording. Mother and 
\ ' 
child reports similarly yielded higher adherence than the two other methods. When 
evaluating the adjusted Doser CT data, which consisted of truncated values to the 
prescribed daily doses, adherence was found tobe low as 50%. (l0) The objective 
25 
data derived from electronic monitoring has also been supported in other studies 
conducted in children comparing electronic devices monitoring with canister 
weight or self-reports. (12;73;74;78) 
Although considered the 'gold standard', electronic devices monitoring are best 
suited for small clinical studies because of the costs and time required to' obtain 
measurements and, are not feasible for retrospective population-based studies. (77) 
For large studies, pharmacy refill records from administrative prescription claims 
databases have been shown to provide efficient and accurate indirect measure of 
'adherence' or medication exposure over time for regular and long term 
medication therapy. (79;80) Few studies to date have used pharmacy refill records 
to measure adherence in asthma patients. These studies are discussed in the 
following section. (75;76) 
Prescription claims databases 
Prescription claims databases typically include the patient identifier, drug code 
which identifies the product name, the unit dose, the form and other product 
information, the quantity of medications dispensed, the duration for each 
dispensed 'prescription and the date of prescription fills. This information is filed in 
the databases for the purpose of reimbursement of drug claims. The' membership 
. depends on the database in question. 
Adherence measured by prescription claims database represents the degree of 
prescription filing in a given interval; a divergence from a9herence couldindicate 
either treatment gaps (undersupply) or drug stockpiling (oversupply). Although 
infrequent, the latter is more likely to occur if the patients are exempt from 
payment. (81) . 
Measures of refill adherence can vary from one another depending' on various 
characteristics. (77;82) For example, the choice of the exposure period for the 
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denominator may differ (e.g. between refills in lieu of study evaluation period). It 
is important to note that when adherence is calculated between refills, it is 
assumed that adherence is consistent through study completion as individuals who 
may discontinue medication prior to study completion are not captured after the 
last refill. This is especially of concem if the denominator (time between refills) is 
mu ch shorter than the study evaluation period which could result in a significant 
overestimation of adherence. (82) The adherence measure may inc1ude or exc1ude 
oversupply in the numerator. When oversupply is not permitted, adherence may 
be underestimated if capping is applied at each refill interval (e.g., excess 
medication is not permitted to carryover from one interval to the next). This is not 
the case when the total supply dispensed is truncated not to exceed the study 
evaluation period. (82) Adherence measure may assess treatment gaps instead of 
medication avaihibility. In the absence of oversupply, the assessment of treatment 
gaps is most attractive when the objective is to identify drug withdrawal effects 
whereas the assessment of medication availability is useful in testing dose-
response effects or the use of medication in general. (77;82) A few examples of 
measures of refill adherence are provided in Table IX under the section entitled 
'Appendices' . 
Two studies conducted in patients with asthma to examine the relationship 
between medication adherence and disease exacerbation have used pharmacy refill 
records to measure adherence. (75;76) 
The first study used the continuous, multiple-interval measure of medication 
availability (CMA) and the continuous, multiple-interval measure of medication 
gaps (CMG) adherence measures which was defined as the total days' suppl y 
dispensed (for CMA) or the total days' treatment gaps (for CMG) divided by the 
total days' between refills during the observation period. These two measures are 
essentially complementary in the absence of oversupplies; the CMA pro vides an 
overall study adherence value based on cumulative drug dosage while the CMG 
'\ ; 
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provides an overall study non adherence value based on the lack of available 
medication. A weakness of the CMG measure is that it cannot distinguish between 
periods of chronic and intermittent under dosing. Moreover, both measures share 
a limitation of not being able to correct for changes in the prescribingpatterns. To 
correct for the latter limitation, the author abstracted the medical records of all 
patients for lCS use and dosage information and ensured that gaps in lCS refills 
were not a result of physicians stopping the prescription. The overall adherence to 
lCS, as estimated by the CMA or CMG, was approximately 50% over a two year 
period. 
The second study used the Medication Possession Ratio (MPR) adherence measure 
which was calculated by dividing the total days' supply dispensed by the total 
days' of study participation which was 365 days for all participants and capped at 
. one to exclude oversupply. It is worth noting that the authors definition ofMPR is 
equivalent to another adherence measurè, the Proportion of Days Covered (PDC), 
discussed under subsection 3.5.2 of this document, as the denominator is the same 
for all participants. This measure provides essentially the same overall adherence 
value as the CMA measure in the absence of changes in the prescribing patterns 
and oversupplies. The authors of this study did not correct for the prescribing 
patterns and reported a median one year adherence ratio of 0.14 for al! controller 
medications (lCS, lCS/LABA, LABA, L TRA, mast cell stabilizers and 
theophylline ). 
A major strength of exposure data found in prescription claims databases isthat it 
is objective as it can be collected independently of the patients and is not subject to 
interview 'social desirability' or recall bias. (12;83) Most databases provide 
complete and accurate exposure data as long as patients are eligible for services. 
(79;80) Other advantages of using prescription daims databases for exposure data 
include being convenient; non-invasive and inexpensive for the obtention of large 
sample sizes. (79;82) 
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A limitation of using prescription claims databases for exposure data is that it can 
overestimate adherence as it reflects drug dispensing and not drug consumption. 
For example, patient may not consume the drug starting the day of dispensing, use 
the drug as prescribed, and consume ail medicationsobtained. (82) Prescription 
claims 'databases are of little use in assessing adherence for drugs used on an as. 
needed basis (PRN), a prevalent management strategy for patients with 
intermittent asthma symptoms. (3) For these patients, a prescribed change in the 
direction of use could lead to higher computed non adherence rates. In the absence 
of medical records, it remains unclear, when using prescription claims databases, 
wh ether little medication refill adherence is attributable to physician non 
adherence to treatment guidelines or patient non adherence to their physicians' 
instructions. Furthermore, databases may include a skewed population and, if not 
representative of the entire population, may have implications on the 
generalizability of the study. (79) 
Despite these limitations, prescription claims databases provide a rich source of 
data for research applications and an effective mean to assess and monitor 
adherence in population-based studies for regular and long term medication 
therapy. (77;79;80;82) 
2.6.3 Prevalence 
Rates of non-adherence among asthmatic patients of ail ages have been reported to 
range from 30% to 70%, regardless of the method of measurements. (84) In 
asthmatic pediatric patients, rates of non-adherence have been reported to range 
from 32% to 50%, wh en using electronic monitoring devices, suggesting no 
evidence of improvement of adherence rates for this age group. (10-12) Among 
pediatric patients, adolescents are less likely to use controller therapy compared to 
younger age groups. (11 ;52;85) Lack of adherence persists in patients with more 
severe asthma, even among those with 2 or more hospitalizations over the previous 
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year suggesting that disease severity may not influence adherence behaviour. 
(67;86-89) 
Overreliance on SABA is still prevalent in children with persistent asthma not 
receiving adequate controller therapy. (86;90-93) For examplè, in a study 
evaluating variability in drug use based on pharmacy daims data in 1093 patients 
aged 7 years and over, it was found that for those· using high doses of SABA, 
defined as more than 8 puffs per day, 37·% did not receive leS and another 31 % 
only received low-dose leS. (93) In another U.S. cross-sectional study, evaluating 
the pattern ofasthma therapy in 13,352 children aged 3 to 15 years old, 40% were 
dispensed a controller therapy (leS or cromolyn) during a one year period, with 
ranges of 15 to 77% by level of SABA dispensing. 'At the highest level of SABA 
dispensing (6 or more SABA), 23% of children had no records of controller 
dispensing. (91) 
There are also several studies which have examined whether les was used as 
prescribed. A survey conducted in adults and parents of children aged 1 to 17 
years revealed that while 75% of patients were using leS, only 38% used les 
daily as prescribed and 40% used leS on an as needed basis. (94) ln a separate 
survey, the frequency ofunder users of controller therapy as reported by parents of . 
children aged 2 to 16 years was 73%, with 49% reporting no controller use and 
24% reporting less than daily use. (95) A review of 10 studies conducted in 
children and adults to measure adherence using electronic device found that 
. patients took les as directed on 20 to 73% of days and took less than 50% of 
prescribed dose on 24 to 69% of days. (96) ln patients 14 to 65 years of age with 
moderate to severe asthma based on the NAEPP severity classification, the 
proportion of respondents who reported having an leS ranged from 55 to 69%. Of 
those respondents who had an leS, less than 50% reported using the inhaler daily 
as recommended by the guidelines. (89) 
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Rates of non adherence among asthmatic patients suggest that inappropriate use of 
controller therapy remains a problem for a majority ofpatients. 
2.6.4 Factors influencing adherence 
. There are many potential factors which have been described to influence 
adherence behaviour of the patients. Sorne ofthese factors are.summarized below. 
Patient-re/ated factors influencing adherence 
The patient's or parent's poor perception of asthma control as weil as their lack of 
understanding of the disease and the role of therapy as highlighted under section 
2.4 are major determinants ofpoor adherence. (61 ;97) Patients are less likely to be 
adherent if they do not accurately perceive their limitation and underestimate the 
severity of their disease. (27;62;98;99) For sorne patients, asthma is only a 
problem when they experience an exacerbation. (62) Underestimating the disease 
1 
may also lead to lack of confidence in the medication prescribed. (27) Patients 
may stop taking leS if they have not experienced an exacerbation for an extended 
period. (100;101) Other patients may stop taking leS prematurely because they 
do not feel an immediate improvement of asthma symptoms. 
(27;62;70;96; 1 00; 1 02) 
Embarrassment or stigrnatization is another factor which may impede adherence' 
especially in adolescents. Adolescents with asthma often feel isolated from their 
peers, and may choose not to take theirmedication in situations that involve social 
barriers. (102; 1 03) 
Psychological dysfunction in patient and family, 'low socioeconomic status and 
level of education have also been associated with problematic adherence. 
(66; 1 00; 1 04-1 06) 
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Treatment-related fàctors influencing adherence 
Treatment-related factors contributing to non adherénce include the choice and 
complexity of the regimerts (e.g. route of medication delivery, multiple daily 
administration or use of multiple diugs), difficulties with inhalation techniques, 
even in healthy children over the age of 5 years, and the patient's perception of the 
side effect profile (2;3;66;70;96;102;107;108) In a U.S. survey identifying issues 
among caregivers that 'could adversely affect adherence, over 80% reported being 
concerned with side effects. (109) Although less common, steroid phobia is still 
an issue. (12;61 ;66;71) For sorne patients, concerns regarding the risk of impaired 
growth of anabolic steroids may incorrectly be assoCiated with ICS. (71) 
2.7 Conclusion 
Asthma is a prevalent chronic respiratory disease especially among children and 
many of these individuals continue to have inadequate asthma control symptoms 
and require emergency care according to recent Canadian surveys .. The treatment 
guidelines advocate the use of ICS as first-line daily long-term use therapy based 
on a wealth of data which have dèmonstrated the efficacy and effectiveness of ICS 
in the symptomatic treatment of asthma. 
Amortg the reasons for the widespread suboptimal control of asthma suggested in 
large surveys, there is a high prevalence of children with persistent asthma not 
being treated with ICS according to guidelines (i.e., daily long-term use of leS). 
Suboptimal use of ICS could potentially be attributable to the physician's non 
adherence to the treatment guidelines and/or the patient's non adherence to their 
-
prescribed regimens. In the U.S., only half of the primary care physicians 
participating in two surveys have reported prescribing ICS for children with 
persistent asthma. In addition, the estimated percentage adherence among 
asthmatic children ranges from 32 to 50%. These studies suggest that both the 
physicians and patients contribute to the suboptimal use of ICS. 
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No studies to date have simultaneouslyassessed the prescribing patterns of leS 
and the patient adherence to this 'medication. 
CHAPTER3: METHODOLOGY 
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This chapter encompasses the methodological aspects presented in the manuscript 
more comprehensively. 
3.1 General research objectives 
To describe the use of lCS in children with persistent asthma, inc1uding both 
prescribing patterns and patierit adherence to the prescribed therapy using a new 
adherence measure. 
3.1.1 Specifie primary objectives 
.1. To develop a new patient adherence measure that takes into account 
variability in prescribing patterns, the Proportion of Prescribed days Covered 
(PPDC); 
2. To estimate the presçription patterns for leS therapyamong asthmatic 
children; 
3. To estimate patient adherence to lCS therapy among asthmatic children using 
the PPDC; 
4. To compare the PPDC with another commonly used patient adherence 
measure, the Proportion of Days Covered (PDC), and estimate the proportion 
of the PDC that is due to variations in prescription patterns. 
3.1.2 Specifie secondary objective 
To describe the frequency of markers of uncontrolled asthma as a function of the 
use of lCS in the year following treatment initiation with lCS. 
3.2 Source of data 
This population-based study utilized data from two of the province of Québec's 
administrative databases; the Régie de l'Assurance Maladie du Québec (RAMQ) 
and the MED-ECHO databases for the period from 1 J anuaiy 1997 through 31 
December 2005. The RAMQ provides medical coverage to all residents of Québec 
and pharmaceutical coverage to the elderly (::::: 65 years), persons receiving social 
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assistance, persons who do not have access to a private msurance plan, and 
children of persons covered by the public plan, which in 2005 represented over 
42% of the population. (110) Al! children covered by the public plan have free 
"access to prescription medications. Prescription c1aims in the RAMQ database is 
only available for insured drugs (i.e. drugs listed on the Québec formulary) 
dispensed from community pharmacies. AlI leS medications are covered by the 
RAMQ drug plan and were permitted in this study (i.e., beclomethasone, 
budesonide, fluticasone and flunisolide). 
The RAMQ database provides information, through a patient unique ideritifier 
(encrypted), related to the patient characteristics such as age, gender, area of 
residence and social aid status, the diagnosis, the encrypted identification and 
specialty of the treating physician, and the identification and date of the dispensed 
medical services as weIl as where they were dispensed - clinics, emergency 
department or hospitals. The RAMQ database also provides information on 
prescription c1aims inc1uding the dru-g code which identifies the product name, the 
unit dose, the form and other product information, the type of prescription (new or 
refill), the number of prescribed refills (potential renewals associated with a new 
prescription), the duration of the prescription, the dispensing date, the encrypted 
identification, and specialty of the prescribing physÏCian. The asthma diagnoses 
and prescription c1aims data recorded in the RAMQ database have been previously 
validated.(80;111) 
The MED-ECHO database provides information on acute care hospital admissions 
inc1uding data on the patient unique identifier (encrypted), the discharge 
diagnoses, and the duration of the hospitalization for all residents of Québec. The 
patient's encrypted unique identifier was used to link the RAMQ database with the 
MED-ECHO database. 
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3.3 Cohort definition 
As shown in Figure 1 under the' Appendices' section, new lCS treatment episode 
were selected retrospectively from the RAMQ database between 1 January 1998 
and 31 December 2004. To ensure a resulting homogenous population with 
respect to the maintenance lCS therapy, new treatment episodes were defined as 
the absence of an lCS dispensation during the 12 months pnor to treatment 
initiation. 
Moreover, prescriptions for adjunct controller therapies consisting of LTRA and/or 
LABA were excluded on the day oftreatment initiation with lCS. lndividuals were 
aged between 5 to 15 years on the day of treatment initiation and needed to be 
enrolled in the RAMQ phannacy insurance plan in the year prior to treatment 
initiation. 
A correct diagnosis of asthma is important for the appropriate pharmacological 
intervention. As asthma syrnptoms are non specific (e.g., recurrent wheezing and 
nocturnal cough), the administration of an objective pulmonary function testing for 
children > 5 years of age is highly recommended by the treatment guidelines to 
help confirm the diagnosis. (2;3) However, pulmonary function testing is rarely 
used and in fact, it was administered to only 50 (2.1 %) children in our cohort. 
To ensure the identification of patients with asthma, we initially applied thé 
following selection criteria in the year before treatinent initiation with lCS: (1) 
diagnosis of asthma (ICD-9 code 493), and (2) utilization of more than 3 doses of 
SABA per week on average, or (3) 1 or more asthma-related event (an emergency 
visit with primary discharge diagnosis of asthma, a hospitalization with primary 
discharge diagnosis of asthma and/or utilization of a short course of OCS) 
indicating the presence of asthma exacerbations. The latter two criteria are 
markers of uncontrolled asthma according to the CAC guidelines and helps 
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confirm the exclusion of patients with misdiagnosed asthma (e.g., patients with 
various forms of bronchitis). 
However, the presence of an asthma-related event may not indicate persis~ent 
asthma symptoms (e.g., patient may have an occasional asthma-related event 
triggered by a viral, upper respiratory tract infection but otherwise be 
asymptomatic). For these patients, optimal treatments have not been clearly 
defined according to the CAC guidelines and, are often treated with intermittent 
ICS therapy. We therefore further restricted our selection criteria to only those 
patients with a diagnosis of asthma and who had used more than 3 doses of SABA 
per week on average in the year before treatment initiation with lCS in order to 
ensure the identification of patients with persistent asthma that would most benefit 
from daily chronic lCS maintenance therapy. 
In addition, we have exc1uded patients with a documented diagnosis for conditions 
whose symptoms overlap those of asthma (i.e., cystic fibrosis (ICD-9 code 277.0) 
or false croup (ICD-9 code 478.75)) or if they had a medication dispensation 
related to these conditions (acetylcysteine, racemic epinephrine, pa)1crelipase, 
pancreatine and tobracymine) or ifthey were oral corticosteroid (OCS) dependent, 
defined as having been dispensed more than 182 days of an OCS, in the year prior 
to treatment initiation to exc1ude. patients with difficult-to-treat asthma or 
conditions other than asthma. 
We also only considered the finit episode oftreatment with lCS and patients with a 
new prescription (not a refill of a previous prescription) 01) the day of treatment 
initiation to ensure that patients had been evaluated by a physician just prior to 
treatment initiation. 
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An assessment period of 12 months following treatment initiation was finally 
considered for aU patients to allow for a long-term assessment of prescribing and 
patient adherence behaviours tothis chronic les therapy. 
3.4 Study design 
A retrospective cohort study design was utilized. 
3.4.1 Justification of the study design 
It is well established that the review of prescription claims data from computerized 
administrative databases such as the RAMQ pharmacy database provides a 
suitable strategy for the long-term monitoring of the use of medications in large 
populations in a real-life setting. (77;82) An important requirement wh en 
assessing adherence (also referred as compliance in sorne studies) to a medication 
regimen from prescription claims data is that the dataset must contain aIl 
prescription claims for the study cohort and the claims data must be complete and 
accurate. The RAMQ database has been validated for this purpose and found to be 
accurate and complete. (80) 
When assessing the validity of adherence measures, we need to consider both the 
sensitivity and specificity of the measures. Within the ccmtext of our study, we 
can define sensitivity as the proportion of adherent patients that is correctly 
identified as adherent while specificity as the proportion of non-adherent patients 
that is correctly' identified as non-adherent. (112) 
It is agreed that refill adherence measures are specific but insensitive of 'partial' 
adherence as it provides an 'upper bound' of medication consumption by assessing 
medication possession. (77) In other words, we could be overestimating 
adherence for patients who do not consume aU medications dispensed. 
Nonetheless, the high specificity of the refill adherence measure aIlows identifying 
and examining patients who are not using sufficient therapy in order to achieve 
control oftheir conditions which meets the objective of our study. 
Moreover, a number of studies have validated measures of refill adherence through 
association with measures of drug presence or drug effect. (77) For example, one 
study reported that pharmacy refill records of centralized pharmacies for patients 
taking an anticonvulsant medication phenytoin correlated significantly (r = 0.31; P 
= 0.03) with mean phenytoin plasma level. (113) In another study, it was found 
that each 10% increase in pharmacy-based refill adherence was statistically 
significantly associated with a decrease of viral load (0.12 log copies/mL; 95% CI 
0.01 to 0.23 log copies/mL) for patients taking antiretroviral therapy. (114) 
Other studies have assessed the predictive validity of measures of refill adherence 
through association with clinical outcomes, health services utilization, or 
healthcare costs. For éxample, one study has found that among community-
dwelling elderly women, noncompliance with alendronate or risedronate assessed 
through the use of prescription claims data was associated with a statistically 
significant increased risk ofnonvertebral fracture (RR: 1.27; 95% CI 1.12 to 1.44). 
(115) 
Refill adherence has also been found to correlate strongly with pill counts (r = 
0.68; P < 0.001). (116) When compared to self-reporting measures, which may 
also be applicable to larger populations, refill adherence is found to be more 
convenient and inexpensive to use, and it is a much more sensitive measure as the 
exposure data is prospectively collected independently of the physicians and 
patients and is therefore not subject to interview 'social desirability' bias and recall 
bias which tends to overestimate adherence. (112) In fact, studies comparing the 
two measures have found that adherence based on refill adherence measures have 
not correlated with self-reported adherence. (114; 117) 
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Furthermore, the RAMQ pharmacy database provides for each prescription 
dispensed, the identification of the type ofprescription (i.e., whether the dispensed 
prescription is a new prescription or a refill of a previous prescription) and the 
number of prescribed refills (i.e., wh en a prescription includes at least one refill, 
the pharinacist records the number of refills prescribed by the physician in the 
RAMQ database). When the prescribed renewals correspond to an end validation 
date, the pharmacist must determine and record thenumber of renewals 
corresponding to the allowed time period or record the number 99 in the field 
pertaining to the number of renewals wh en the number of prescribed renewals 
cannot be determined precisely. The RAMQ pharmacydatabase also provides the 
duration of prescriptions which is determined by the pharmacists based on the 
supplied quantity divided by the prescribed dose. These variables are available as 
soon as a new prescription has been dispensed and can be used to estimate the total 
number of prescriptions (new and refills) prescribed by the physicians without 
having to consult the patients' medical records. This information allows the 
determination of the physicians' prescribing pattern and the identification of 
whether suboptimal use of medication can be attributable to physicians' under 
prescribing and/or the patients' non adherence to their prescribed regimen. 
3.5 Outcomes definitions 
. 3.5. J Prescribing patterns 
We estimaied the prescribing patterns by reporting the total number of 
prescriptions for leS which was defined as the sum of all new prescriptions 
dispensed plus prescribed refills from ail physicians a patient could have consulted 
during the 12-month follow-up period. The numbers of new prescriptions 
dispensed and prescribed refills were also reported separately. The sum of the 
duration of all prescriptions of leS was th en calculated to determine the total days' 
supply prescribed during the study period. 
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Total days' supply prescribed 
Physicians' adherence 
Total d'ays' of study duration 
The numerator was truncated to 365 days to exclude. excess medication 
prescription. 
3.5.2 Patient adherence 
Adherence to a drug regimen as defined under section 2.6.1 is the extent to which 
a patient's actual history of drug administration corresponds to the agreed upon 
prescribed regimen. (2;70;71) lnitially, a measure of refill adherence frequently 
used in previous studies was explored. This adherence measure, referred as the 
Proportion of Days Covered (PDC), is defined as the ratio of the total days' 
supplies dispensed by the duration of the study as shown below: 
Total days' supply dispensed 
PDC 
Total days' ofstudy participation 
We noted that although the PDC adherence measure provides an accurate 
reflection of the use of medication throughout the duration of the study, it may not 
accurately reflect patient adherence to their prescribed medication if the latter is 
not prescribed for daily long-term use. In the presence of differing prescribing 
patterns, the PDC may fail to provide information about whether the patient is 
using the medication as prescribed. 
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It is for this reason that we have developed a new treatment adherence measure for 
the study presented herein wh'ich we named the Proportion of Prescribed Days 
Covered (PPDC). The PPDC which is based on the PDC rrieasure is defined as the 
total days' supply dispensed to the total days' supply prescribed during the 12-
month follow-llp period. The total days' supply dispensed was calculated by 
sllmming the duration of ail prescriptions of ICS (new and refilIs) dispensed from 
ail physicians over the 12-month follow-up period as shown below: 
Total days' supply dispensed 
PPDC 
Total days' supply prescribed 
Both numerator and denominator were truncated to 365 days to excillde excess 
medication possession and medication prescription, respectively. 
Patient adherence was estimated for ail patients as well as stratified by prescription 
categories (1 prescription, 2 to 6 prescriptions and 2: 7 prescriptions) to describe 
patients' adherence behaviour among those prescribed episodic and chronic lCS 
therapy. Patient adherence was also estimated for the two age groups (5-11 years 
and 12-15 years) separately. For comparison, we also estimated the overall patient 
adherence llsing the PDC. 
In addition, the proportion of the non adherence value attributable to the lack of 
prescribing daily long tertn therapy was estimated using the following formula: 
(1 - PDC) - (1- PPDC) 
(1- PDC) 
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where 1 - PDe = 1 - (total days' supply dispensed/study duration) .and represents 
the non adherence measure of the patients that includes the effect of the 
prescribing patterns and 1 - PPDe = 1 - (total days' supply dispensed/total days' 
supply prescribed) and represents the non adherence measure of the patients that 
corrects for the effect of the prescribing patterns .. 
We did not assess therapy persistence m our study, which exammes more 
specifically the act of continuing therapy for the prescribed duration, byreporting 
the proportion of patients continuing to use a therapy after specified time intervals 
during the study period. (118) Although therapy persistence is often reported for 
chronic preventive therapies, it is difficult to assess in asthmatic patients as many 
physicians do not prescribed leS for daily long term use (please see subsection 
2.5). 
3.5.3 Markers ofuncontrolled asthma 
We have described markers of uncontrolled asthma which are commonly used in 
administrative databases studies. (75; 119) Markers of uncontrolled asthma over 
the 12-~onth follow-up period included moderate to severe asthma exacerbations 
which was defined as a composite outcome of a dispensed prescription for a short 
course oes (14 days or less), an asthma-related emergency department visit or an 
asthma-related hospitalization. As shown below, the date of the first event 
constituted the beginning of the exacerbation. Exacerbations occurring within 15 
days of a previous exacerbation were excluded to avoid double counting of the 
same event. 
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The three elements of this composite outcome were also reported separately. 
These markers of uncontrolled asthma were classified as dichotomous variables 
(O/~ 1). Furthermore, we have assessed SABA use as a marker of asthma control 
based on the average number of doses per week and categorized into 3 groups: 0-3 
doses per week, >3-10 doses per week and> 10 doses per week, 
3.6 Characteristics of the patients and physicians 
The patient characteristics which we described iricluded demographics at treatment 
initiation, co-morbid conditions such as diseases of the upper respiratory tract 
, (ICD-9 codes: 460 (acute nasopharyngitis [common cold]), 461 (acute sinusitis), 
465 (acute upper respitatory infections ofmultiple or unspecified sites), 466 (acute 
bronchitis and bronchiolitis), 471 (nasal polyps), 472.0 (chronic rhinitis), 473 
(chronic sinusitis), 477 (allergic rhinitis), pneumonia and influenza (ICD-9 codçs: 
480 (viral pneumonia), 482 (other bacterial pneumonia), 483 (pneumonia due to 
other specified organism), 484 (pneumonia in infectious diseases classified 
elsewhere), 485 (bronchopnellmonia, organism lInspecified), 486 (pneumonia, 
organism unspecified) and 487 (influenza), gastro-oesophageal reflux disease 
(ICD-9 code: 530.8), use of medications related to respiratory diseases (e.g., anti· 
allergy therapies, corticosteroids for nasal use and oral SABA), use of OCS, 
average number of doses of SABA used per week, number of moderate to severe 
asthma exacerbations, outpatient visits for asthma and for all causes (asthma and 
other diagnoses), and emergency departnient visits and hospitalizations due to 
asthma. assessed in the year prior to treatment initiation. Characteristics related to 
( 
> 15days 
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the first prescription of lCS included the prescribed daily dose categorized into 
three groups (>0-250 p.,g per day, >250-500 p.,g per day and >500 p.,g per day), type 
of lCS, specialty of the prescribing physician, location of the prescribing 
physicians, number of prescribed refills as weIl as the presence of markers of 
uncontrolled asthma (use of OCS, asthma-related emergency department visits, 
hospitalizations due to asthma and moderate to severe asthma exacerbations) at 
treatment initiation and 15 days prior. During the 12-month foIlow-up period, we 
assessed variables reflecting the use of health care services including the number 
of different prescribing physicians for asthma medications and the number of 
outpatient visits for asthma (at 6 weeks, 3 months and 12 months time points) and 
the number of outpatient visits for aIl causes (asthma and other diagnoses). 
Moreover, we estimated the average daily doses of lCS during the 12-month 
follow-up period for the two to six and seven or more prescriptions categories 
only, since the calculation of the average daily dose ofICS over a 12-month period 
is irrelevant when the patient had only received one prescription ofICS. 
Events preceding each new and refill prescription dispensations (dispensing date 
and prior 15 days) such as moderate to severe asthma exacerbation, asthma-related 
emergency department visits, hospitalizations due to asthma and use of OCS were 
exainined during the follow-up period. The observation period included 15 days 
prior to a dispensation to ensure capturing events for patients who may not o1:5tain 
their prescriptions the day the medication is prescribed. 
Patients were allowed to switch lCS medicatiorts during the follow up period. lCS 
medications were reported into fluticasone-equivalent based on equivalencies 
provided in the CAC guidelines and SABA medications were converted to dose 
equivalencies between the different SABA agents using tpe algorithm suggested 
by Blais et al.(120) 
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This study was approved by the Scientific and Ethics Committee of the Hôpital du 
Sacré-Cœur de Montréal, Québec, Canada. 
3.7 Statistic analyses , 
Descriptive statistics were used to summarize the characteristics related to the 
patients 12-month prior to and 12-month following treatment initiation as weIl as 
to the physicians 12-month following treatment initiation. Data were reported as 
both medians and means with 95% confidence intervals for the prescribing 
patterns, use of health care services, patient adherence, and average daily doses of 
lCS; and as proportions for the markers of asthma control. Markers of 
uncontrolled asthma were stratified by three prescription categories (one 
prescription, two to six pre~criptions and seven or more prescriptions) and by two 
patient adherence categories (2:50% and <50%). All statistical analyses were 
performed using SAS software version 9.1 (SAS Institute, Cary, NC). 
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The objective of this chapter is to supplement the results presented ln the 
manuscript. Results presented under the manuscript are not repeated in this 
chapter. All tables referred below are found under the section entitled 
, Appendices' . 
The locations of the prescribing physicians for the initial prescription of ICS are 
presented in Table 1. Among the available locations (62%), the majority of 
prescriptions were obtained at outpatient clinics (75.7%) followed by emergency 
departments (20.5%) and hospitals (3.7%). Fewer patients received prescribed 
refills from emergency departments (39.1 %) than from outpatient clinics (56.4%) 
and hospitals (51.9%). 
In order to avoid overestimating the prescribing patterns and patient adherence to 
ICS during the study follow-up period, we have truncated the total days supply 
prescribed and the total days supply dispensed to 365 days affecting 5 to 10% and 
less than 1 % of the patients, respectively. 
As shown in Table II, the overall median physicians' adherence to the CAC 
guidelines recommendation for the prescription of ICS for persistent asthma, 
representing the number of days of prescribed daily dose during the 12-month 
follow-up period, was 32.9%. When determining the overall median physicians' 
adherence to the CAC guidelines, we have found 267 new prescriptions (6.6%) 
with a recorded end validation date for potential renewals affecting 228 patients 
(9.7%). The majority of these prescriptions were valid for a duration of 365 days. 
The first analysis consisted of assigning the maximum potential number of 
renewals for the 267 new prescriptions with a recorded end validation date while 
-the second analysis consisted of removing from the analyses the 228 patients who 
had at least one prescription with an end validation date. As shown in Table III, 
the oveiall median physicians' adherence to the CAC guidelines during the 12-
month follow-up period obtained from the first and second sensitivity analyses 
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was 34.2%and 32.9%, respectively and the overall median patients' adherence 
rates obtained from the first and second sensitivity analyses was 50.0% and 53.8%, 
respectively. 
Table IV pres"ents adherence to the CAC guidelines for .the re-evaluation of asthma 
control and effectiveness of the prescribed maintenance therapy. The number of 
patients with at least one outpatient visits for asthma at 6 weeks and 3 months 
i 
following treatment initiation were 13.4% and 21.0%, respectively. The number 
of patients with at least one outpatient visits for asthma during the 12-month 
follow-up period was 45.4%. 
As shown in Table V, the overall median patient adherence rat~ during the 12-
month follow-up period was 58.6% when calculated using the newly developed 
PPDC measure compared to 15.1 % w hen calculated using the PDC measure. The 
proportion of the non adherence value attributable to the lack of prescribing daily 
long-term ICS therapy is 51.2%. The comparison of adherence rates among 
children aged 5to Il years with those aged 12 to 15 years during the 12-month 
follow-up period are presented under Table VI. The median patient adherence rate 
obtained from the PPDC measure was 61.5% for the younger age group compared 
J 
to 52.4% for the older age group. Similarly, the median patient adherence rates 
among children who had seven or more prescriptions were 32.9% and 28.9% for 
the younger and older age groups, respectively. 
Table VII presents asthma-related events occurring 15 days prior to or on the day 
of an ICS dispensation throughout the 12-month follow-up period. Moderate to 
severe exacerbations preceded 14% of aIl prescriptions dispensed (new and refills) 
and were more frequent prior to a dispensation of a new prescription (18.l %) 
compared to a refill prescription (2.2%). 
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The number of patients with controlled asthma stratified by the number of 
prescription categories and patient adherence during the 12-month follow-up 
period is presented in Table VIII. Overall, patients with controlled asthni.a based 
on an average use of 3 doses or less of SABA per week, on average, and the 
absence of exacerbations represented 25% of the cohort The number of patients 
with controlled asthma decreased with increasing leS exposure. 
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ABSTRACT 
The objective of this study was to measure simultaneously patient adherence and 
prescribing patterns of inhaled corticosteroids in asthmatic children with a new 
adherence measure. 
A cohort of 2,355 children aged 5-15 years with asthma and having had used > 3 
doses of short-acting beta-agonists per week on average during a 12-month period 
prior to treatment initiation with inhaled corticosteroids was reconstructed using 
Canadian administrative databases, between 1997 and 2005. 
During the 12-month follow-up period, 20% of the children received only 1 
prescription of inhaled corticosteroids with no prescribed renewals. The median 
number of prescriptions (including prescribed renewals) was 4 corresponding to 
only 120 days' supply prescribed. The median percent patient adherence to the 
prescribed therapy was 58.6%. Only 25% of the patients had controlled asthma 
based on the use of ~ 3 doses of short-acting beta-agonists per week and absence 
of moderate to severe exacerbations. 
A large percent age of children with persistent asthma were not prescribed inhaled 
corticosteroids for chronic daily use and patient adherence was suboptimal. Many 
of these patients continued to experience poor asthma control. 
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Introduction 
Asthma is one of the most common chronic conditions in childhood. In Canada, 
approximately 15.6% of children aged 4 to 11 years and 11.7% aged 12 to 19 
years have been diagnosed with asthma.[I] Despite widely distributed treatment 
guidelines including the Canadian Asthma Consensus (CAC) guidelines [2;3] and 
therapeutic advances aimed at preventing the ons et of symptoms and providing 
long-term control of asthma symptoms, Canadian surveys continue to show a 
significant gap between treatment goals and levels of asthma control.[2;4] As a 
result, patients continue to experience poor asthma control and thus, require 
emergency care.[1 ;5] 
Lack of adoption to the pharmacological therapy recommendations of the 
treatment guidelines may be one aspect contributing to suboptimal asthma control. 
Surveys conducted in the United States (U.S.) in 1999 and 2004 found that only 
half of the primary care physicians reported adherence to guideline 
recommendations for the prescription of daily ICS for children with persistent 
asthma.[6;7] Recently, a Canadian study surveying primary care physicians found 
that 20% of uncontrolled patients used SABA al one and the most frequently 
reported recommended change for these patients was the initiation of ICS, but in 
only 52% of them.[8] Moreover, rates of non-adherence to ICS in asthmatic 
paediatric patients have been reported to range from 32% to 50% through the use 
of electronic monitoring devices.[9-11] 
Use of ICS has also been assessed using administrative data. A recent Canadian 
retrospective study conducted by Klomp et al has found that among those with 
poor asthma control, 37% were not dispensed any ICS.[12] The findings of this 
study are consistent with previous studies conducted in both Canada and the 
U.S.[13;14] However, it remains unclear from these studies whether the 
suboptimal use of ICS is attributable to physicians' non adherence to treatment 
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guidelines for the prescription of ICS as maintenance therapy or patients' non 
adherence to their prescribed regimen. 
To our knowledge, there are no studies using administrative data that have 
simultaneously assessed the prescribing patterns of ICS and the adherence to this 
medication. Using administrative daims data from the province of Québec 
( 
(Canada), the primary objective of this study was to describe the use of ICS in 
children with persistent asthma, inc1uding both prescribing patterns and patient 
adherence to prescribed ICS therapy using a new adherence measure. A secondary 
objective of this study was to describe markers of uncontrolled asthma as a 
function of the use of ICS. 
Methods 
Data Source 
, 
This study was completed using data from two of the province of Québec's' 
administrative databases; the Régie de l'Assurance Maladie du Québec (RAMQ) 
and the MED-ECHO databases for the period from 1 January 1997 through 31 
December 2005. The RAMQ provides medical coverage to aIl residents of Québec 
and pharmaceutical coverage to the elderly (~ 65 years), persons receiving social 
assistance, persons who do not have access to a private insurance plan, and 
children of persons covered by the public plan, which in 2005 represented over 
42% of the population. Ali children covered by the public plan have free access to 
prescription medication. 
The RAMQ database provides information, through a patient unique identifier 
(encrypted), related to the patient characteristics such as age, gender, area of 
residence and social aid status, the diagnosis, the encrypted identification, 
specialty of the treating physician, and type & date of the dispensed medical 
services as weIl as where they were dispensed - dinics, emergency department or 
hospitals. The RAMQ database also provides information on prescription daims 
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including the drug code which identifies the product name, the unit dose, the fonn 
and other product infonnation, the type of prescription (new or refill), the number 
of prescribed refills (potential renewals associated with a new prescription), the 
duration of the prescription, the dispensing date, the encrypted identification, and 
specialty of the prescribing physician. The asthma diagnoses and prescription 
claims data recorded in the RAMQ database have been previously 
validated. [15; 16] 
The MED-ECHO database provides infonnation on acute care hospital admissions 
including data on the patient unique identifier (encrypted), the dis charge 
diagnoses, and the duration of the hospitalization for all residents of Québec. The 
patient' s encrypted unique identifier was used to link the RAMQ database with the 
MED-ECHO database. 
Cohort Definition 
Patients with a newly filled prescription for an ICS in monotherapy were 
retrospectively selected from the RAMQ database between 1 January 1997 and 31 
December 2004. The inclusion criteria were being between 5 and 15 years of age 
at treatment initiation with ICS (date of the first filled prescription of ICS which 
defined cohort entry), having received a diagnosis of asthma (lCD-9 code 493), 
and having used more than three doses of SABA per week on average in the year 
prior to treatment initiation to ensure that only patients with persistent asthma were 
included in the study. Patients had to have pharmaceutical insurance coverage one 
year prior to treatment initiation and throughout the follow-up period. Patients did 
not qualify for the study if they filled a prescription for an ICS in the year prior to 
treatment initiation or for a leukotriene modifier and/or a long-acting beta-agonist 
at treatment initiation and throughout the foBow-up period. AB patients were 
followed for a period of 12 months. Patients were excluded if they had a diagnosis 
of cystic fibrosis (ICD-9 code 277.0) or false croup (lCD-9 code 478.75), if they 
had been dispensed a prescription for an acetylcysteine, racemic epinephrine, 
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pancrelipase, pancreatine and tobracymine or if they were oral corticosteroid 
(OCS) dependent, rlefined as having been dispensed more than 182 'days of an 
OCS, in the year prior to treatment initiation. 
Outcomes 
The primary outcomes were the prescribing patterns of lCS and patient adherence 
to lCS. Markers of uncontrolled asthma were secondary outcomes. 
Prescribing Patterns of ICS 
To de scribe the prescribing patterns, we reported the total number of prescriptions 
for lCS which was defined as the sum of aIl new prescriptions 'dispensed plus 
prescribed refills (i.e., when a prescription included at least one refill, the 
pharrnacist records the number of refills prescribed by the physician in the RAMQ 
database) from aIl physicians a patient could have consulted during the 12-month 
foIlow-up period. The numbers of new prescriptions dispensed and prescribed 
refills were also reported separately. The sum of the duration of the total number 
of prescriptions of lCS was then calculated to deterrnine the total days' supply 
prescribed. 
Patient Adherence to ICS 
A new treatment adherence measure which we named the Proportion of Prescribed 
Days Covered (PPDC) was developed for this study to account for differing 
prescribing patterns. The PPDC was defined as the total days' supply dispensed to 
the total days' supply prescribed during the 12-month foIlow-up period. The total 
days' suppl Y dispensed was calculated by summing the duration of the dispensed 
prescriptions of lCS (new and refills) over the 12-month follow-up period. 
Total days' supply dispensed 
PPDC= 
Total days' supply prescribed 
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Both numerator and denominator were truncated to 365 days to exclude excess 
medication possession and medication prescription, respectively. 
Patient adherence was estimated for aIl patients as weIl as stratified per 
prescription categories (one prescription, two to six prescriptions and seven or 
more prescriptions) to describe patients' adherence behaviour among those 
prescribed episodic and chronic ICS therapies. Patient adherence was also 
estimated for the two age groups (5-11 years and 12-15 years) separately. 
Markers of Uncontrolled Asthma 
Markers of uncontrolled asthma over the 12-month follow-up period included 
moderate to severe asthma exacerbations, which were defined as a composite 
outcome of a dispensed prescription for a short course DCS (14 days or less), an 
asthma-related emergency department visit, or an asthma-related hospitalization. 
The date of the first event constituted the start of the exacerbation. Exacerbations 
occurring within 15 days of a previous exacerbation were excluded to avoid 
double counting of the same event. The three elements of this composite outcome 
were also reported separately. These markers were classified as dichotomous 
variables (021). Furthermore, we have assessed SABA use as a marker of asthma 
control based on the average number of doses per week and categorized into three 
groups: 0-3 doses per week, 4-10 doses per week and >10 doses per week. 
ICS medications were reported into fluticasone-equivalent based on equivalencies 
provided in the CAC guidelines and SABA medications were converted to dose 
equivalencies between the different SABA agents using the algorithm suggested 
by Blais et al.[17] 
This study was approved by the Scientific and Ethics Committee of the Hôpital du 
Sacré-Cœur de Montréal, Québec, Canada. 
59 
Statistical Analyses 
Descriptive statistics were used to summarize the characteristics related to the 
patients 12-month prior to and 12-month following treatment initiation as well as 
to the physicians 12-month following treatment initiation. Data were reported as 
both medians and means with 95% confidence intervals for the prescribing 
patterns, use of health care services, patient adherence, and average daily doses of 
ICS; and as proportions for the markers of asthma control. Markers of 
uncontrolled asthma were stratified by three prescription categories (one 
prescription, two to six prescriptions and seven or more prescriptions) and by two 
patient adherence categories (2::50% and <50%). AIl statistical analyses were 
performed using SAS software version 9.1 (SAS Institute, Cary, NC). 
Results 
A total of 2,355 ICS-naïve children with persistent asthma met the study criteria. 
Baseline characteristics of the study population are shown in Table 1. The majority 
of patients (67.3%) were 5 to 11 years of age, male (56.4%), residing in urban 
are as (78.7%), and 40.3% were children of families receiving social assistance. 
During the year prior to treatment initiation with ICS, 40.5% of children had 
received a diagnosis for comorbid diseases of the upper respiratory tract, 10.9% 
had received a diagnosis related to pneumonia and/or influenza while none of the 
children had received a diagnosis of gastro-oesophageal reflux disease. As many 
as 13.2% of children had used an average of more than 10 doses of SABA per 
week and 28.3% had experienced at least one moderate to severe asthma 
exacerbation in the year prior to treatment initiation with ICS. 
We then examined the characteristics related to the initial ICS prescription as 
shown in Table 2. For almost half of the patients (47.6%), there was no prescribed 
refill with their initial prescription and as much as 20.2% had experienced a 
moderate to severe exacerbation just prior to or on the day of the initiation of the 
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treatment with ICS. Among children with prescribed refills, the median number of 
refills was 1.0. Almost 95% of prescribers were family physicians and 
pediatricians. 
Table 3 presents the prescribing patterns, use of healthcare services and patient 
adherence to ICS during the 12-month follow-up period. Twenty percent of the 
children received only one new prescription of ICS (no prescribed refills) and 50% 
had only 4 or fewer prescriptions from aIl physicians consulted during the 12-
month foIlow-up corresponding to 120.0 days' supply prescribed. The median 
number of prescribing physicians was 2.0, with one outpatient visit for asthma and 
four outpatient visits for aIl causes. The overall median patient adherence value 
during the 12-month foIlow-up period was 58.6% and as low as 31.5% among 
children who had seven or more prescriptions. The median average daily dose of 
ICS was 73.2 and 118.7 Ilg per day among children who had two to six and seven 
or more prescriptions, respectively. 
Markers of uncontrolled asthma stratified by prescription and patient adherence 
categories during the 12-month follow-up period are presented under Table 4. The 
continued high use of SABA and frequencies of moderate to severe exacerbations 
indicate that many patients were inadequately controlled during the follow-up. 
Discussion 
The prescribing patterns that we have identified suggest that ICS is often not 
prescribed for daily long-tenn use as recommended by the CAC guidelines for 
patients with persistent asthma. Indeed, during the 12-month follow-up period, 
20% of patients had received only one prescription of ICS and 50% had 4 or fewer 
prescriptions corresponding to 120 days' suppl y prescribed. It is worth noting that 
regular use of ICS was clearly indicated for aIl patients in our cohort since they aIl 
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used on average more than three doses of SABA per week in the year prior to the 
first prescription of leS. 
There are many potential barriers to prescribing leS that may explain our findings 
including lack of agreement with the leS guidelines, lack of familiarity with 
guidelines criteria of asthma control, concems regarding potential side effects of 
corticosteroids, and family-Ievel barriers such as the cost of the medication which, 
in our study, is not a barrier since aIl patients had free access to their medications. 
[6;7;18] Our data suggest that for sorne patients, leS may be used only to manage 
exacerbations. lndeed, we found that 20.2% of children had experienced a 
moderate to severe exacerbation just prior to or on the day of their initial leS 
prescription. During the foIlow-up period, 27.1 % of children with seven or more 
prescriptions had experienced a moderate to severe exacerbation excluding those 
occurring on the day of treatment initiation compared to 21.3% among children 
with two to six prescriptions and 13% among children with one prescription. We 
have also found that patients had few regular foIlow-up visits for as th ma with their 
physicians which may also explain the under prescribing of leS. Moreover, the 
median number of different prescribing physicians consulted was two indicating 
that patients have less than optimal continuity of care for the treatment of 
asthma.[19] 
ln addition to the suboptimal prescription of les by physicians, the overall median 
patient adherence value during the 12-month follow-up period was 58.6% and as 
low as 31.5% among children who had seven or more prescriptions. These results 
are consistent with the adherence rates reported in the literature. [9-11 ;20] As 
anticipated, the 12 to 15 age group had a lower overaIl median adherence than the 
younger age group (52.4% versus 61.5%), which is also consistent with the 
literature. [ 10; 13 ;2l] 
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Poor adherence to prescribed ICS therapy can be a result of many different 
underlying causes.[22;23] For sorne patients, asthma is only a problem when they 
experience an exacerbation. [24] Misunderstanding the role of therapy is also 
common in parents of children with persistent asthma.[25] 
This study also showed that many patients did not attain control of their asthma by 
the observed frequencies of moderate to severe exacerbations and the continued 
high use of SABA during the follow-up period highlighting the importance of 
treating asthma with maintenance ICS therapy. In fact, only 25% of the patients 
had controlled asthma based on low use of SABA (three doses or less per week on 
average) and absence of moderate to severe exacerbations (data not shown). We 
observe that our two markers of uncontrolled asthma increases with increased ICS 
exposure. However, the majority of the patients had a median average daily dose 
below 125 jJg, which may not be sufficient for patients with uncontrolled asthma. 
There are several important methodological strengths to our study. We have 
selected patients who would most likely benefit from chronic daily use of ICS 
therapy as ail patients had used more than three doses of SABA per week on 
average, a guideline defined marker of poor asthma control, during the one year 
period prior to treatment initiation. We have used a large validated healthcare 
administrative database to assess the use of ICS, which provides prospectively 
collected data on a population level. We were able to identify whether the low use 
of ICS was attributable to physicians not prescribing ICS for chronic daily use 
and/or the patient not filling their prescriptions using our newly developed 
adherence measure, the PPDC, which takes into account the quantity of 
medication prescribed, thereby correcting for the effect of varying prescribing 
patterns. Indeed, we would have obtained a median adherence value of 15.1% 
(data not shown) had we used the proportion of days covered (PDC), a frequently 
used adherence measure, instead of 58.6% when using the PPDC measure.[26] 
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Our findings must be interpreted in light of sorne limitations. Our study excluded' 
patients covered by private drug plans; families with higher income may have been 
underrepresented. However, a previous Canadian study has shown that 
socioeconomic status had little influence on medication prescription patterns for 
the treatment of asthma in a population of children that had free access to 
prescribed medications. [17] Our findings may not generally apply to populations 
that pay for their medications. Our inability to determine whether patients booked 
and kept follow-up appointments with their physician and whether patients have 
filled their new prescription may have resulted in an underestimation of the 
prescribing patterns as only prescriptions dispensed at the pharmacy are accounted 
for in the database.[27] Conversely, the prescribing patterns were based on the 
total number of prescriptions a patient could have received from aIl physicians 
consulted during the 12-month follow-up period, which may overestimate the 
prescribing patterns of individual physicians. The adherence value derived from 
administrative databases assumes that patients filled their new prescription, used 
the drug as prescribed, and consumed aIl medications, thus providing the highest 
potential adherence. 
Our study showed that many children with persistent asthma did not use their 
newly prescribed ICS therapy on a daily chronic basis, continued to overuse 
SABA, and experienced moderate to severe exacerbations. The consequences of 
poor compliance with the CAC guidelines recommendation to use ICS as 
maintenance therapy for patients with persistent asthma have been shown to 
reduce the effectiveness of the medication regimen, increase symptoms as weIl as 
being associated with a significantly higher number of annual emergency and 
hospitalization visits.[28-30] Our efforts to disentangle the behaviours of 
physicians and patients regarding the use of ICS therapy can be very useful in 
providing a better understanding of the gap between treatment goals and asthma 
control and in the planning of interventions aiming at the optimal use of ICS 
therapy. 
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T bl 1 Ch a e aractenstlcs 0 fth S dPI . e tU!y opu atIon 
Number of patients 2355 
Variables Number (%) 
At treatment initiation 
Age (years) 
5-11 1584 (67.3) 
12-15 771 (32.7) 
Male gender 1329 (56.4) 
Area of residence 
Urban 1852 (78.7) 
Rural 500 (21.3) 
Missing '\ 3 (0.1) 
Social aid recipients 950 (40.3) 
One year prior to treatment initiation 
Comorbidities: 
Diseases of the Upper Respiratory Tract 954 (40.5) 
Pneumonia and Influenza 257 (10.9) 
Dispensed prescription related to respiratory diseases: 
Anti-aUergy therapies 16 (0.7) 
Corticosteroids for nasal use 305 (13.0) 
Oral short-acting beta-agonists 85 (3.6) 
Number of out patient visits for asthma 
0 888 (37.7) 
1 972 (41.3) 
~2 495 (21.0) 
~ one pulmonary function test 50 (2.1) 
Use of SABA 
>3-10 doses per week 2043 (86.8) 
> 10 doses per week 312 (13.2) 
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Number of patients 2355 
Variables Number(%) 
~ one dispensed prescription of oes (14 days or less) 389 (16.5) 
~ one visits to an emergency department for asthma 492 (20.9) 
~ one hospitalizations for asthma 103 (4.4) 
~ one moderate to severe asthma exacerbation 666 (28.3) 
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Table 2: Characteristics Related to the Initial Prescription 
Number of patients 2355 
Variables " Number (%) 
At treatment initiation 
Fluticasone-equivalent dose prescribed, in Jlg per day, 
>0-250 424 (18.0) 
>250-500 809 (34.4) 
>500 1122 (47.6) 
Type of ICS 
Fluticasone 1564 (66.4) 
Budesonide 580 (24.6) 
Beclomethasone 211 (9.0) 
Number of prescribed refills 1 
0 1122 (47.6) 
2: 1 1233 (52.4) 
Median (95% CI) 1.0 (1.0-1.0) 
Mean (95% CI) 2.2 (2.0-2.3) 
Prescribing physician specialty 
Family physician 1579 (67.0) 
Pediatrician 657 (27.9) 
Pneumologist 37 (1.6) 
Other 82 (3.5) 
At treatment initiation and prior 15 days 
2: one dispensed OCS 298 (12.7) 
2: one visit to an emergency department for asthma 367 (15.6) 
2: one hospitalization for asthma 51 (2.2) 
2: one moderate to severe asthma exacerbation 476 (20.2) 
1 Truncated to 365 days 
71 
Table 3: Prescribing Patterns, Use of Healthcare Services and Patient Medication 
Adherence during the 12-month PoIlow-up Period 
Number of pati~nts 
Variables 
Prescribing patterns of ICS 
Number of dispensed new prescriptions 
Number of prescribed refills 
Total number of prescriptions 
Total days' suppl Y prescribed 
Use of health care services 
Number of different prescribing 
physicians for asthma medications 
Number of outpatient visits for asthma 1 
Number of outpatient visits aIl causes 1 
Patient adherence to ICS 
AB patients 
Patients with 1 prescription (n=468) 
Patients with 2-6 prescriptions (n=1270) 
Average leS dose2, in Jlg per day, 
Patients with 2: 7 prescriptions (n=617) 
Average les dose2, in Jlg per day, 
J ... lncludes 15 days pnor to treatment InItIatIOn 
2PI uticasone-equi valent dose 
2355 
Median (95% CI) Mean (95% CI) 
1.0 (1.0-1.0) 1.7 (1.7 -1. 7) 
2.0 (2.0-2.0) 3.3 (3.1-3.5) 
4.0 (4.0-4.0) 5.0 (4.9-5.2) 
120.0 (105.0-120.0) 152.0 (146.5-157.4) 
2.0 (2.0-2.0) 1.9 (1.9-2.0) 
1.0 (1.0-1.0) 1.3 (1.2-1.3) 
4.0 (4.0-4.0) 5.1 (4.9-5.3) 
58.6 (54.8-62.5) 62.4 (61.1-63.7) 
100.0 (100.0-100.0) 100.0 (100.0-100.0) 
55.8 (50.7-60.0) 60.9 (59.3-62.5) 
73.2 (68.3-78.4) 87.9 (84.7-91.2) 
31.5 (28.9-33.9) 36.8 (35.1-38.6) 
118.7 (106.4-126.3) 143.6 (135.2-152.0) 
Notes: The number of prescribed refills, total number of prescriptions, total days' 
supply prescribed, patient adherence and average daily dose of les were truncated 
to 365 days. The average daily dose of les was not ca1culated for patients who 
had received only one prescription over the 12-month follow-up period as it is 
irrelevant. 
72 
Table 4: Markers of Uncontrolled Asthma during the 12-month Follow-up Period 
as a Function of the Use of ICS 
Use of les 
Total number of prescriptions 1 2-6 ?7 
Patient adherence, % 100% <50% 
1 
' ?50% <50% 
1 
?50% 
Markers of uncontrolled asthma 
Number of patients 468 469 801 475 142 
Use of SABA, (%) 
0-3 doses per week 262 (56.0) 159 (33.9) 164 (20.5) 74 (15.6) 8 (5.6) 
4-10 doses per week 174 (37.2) 246 (52.5) 490 (61.2) 272 (57.3) 46 (32.4) 
> 10 doses per week 32 (6.8) 64 (13.6) 147 (18.4) 129 (27.2) 88 (62.0) 
2: one dispensed OCS, (%) 32 (6.8) 58 (12.4) 157 (19.6) 93 (19.6) 36 (25.4) 
2: one visit to an emergency 
department for asthma, (%) 47 (10.0) 55 (11.7) 117 (14.6) 81 (17.1) 33 (23.0) 
2: one hospitalization for 
asthma,(%) 6 (1.3) 4 (0.9) 18 (2.2) 12 (2.5) 9 (6.3) 
2: one moderate to severe 
exacerbation, (%) 61 (13.0) 81 (17.3) 189 (23.6) 117 (24.6) 50 (35.2) 
1 .. exc1udmg the day of treatment InitiatIOn 
CHAPTER 6: DISCUSSION 
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This chapter encompasses the discussion of the results presented in the manuscript 
as well as those presented under chapter 4. 
The. prescribing patterns that we have identified suggest that lCS is often not 
prescribed for daily long-tenn use as recommended by the CAC guidelines for 
patients with persistent asthma. lndeed, during the 12-month follow-up period, 
20% of patients had received only one prescription ofICS and 50% had 4 or fewer 
prescriptions corresponding to 120 days' supply prèscribed. It is worth noting that 
. \ 
regular use of lCS was c1early indicated for all patients in our cohort since they all 
used on average more than three doses of SABA per week in the year prior to the 
first prescription of lCS. 
We have also found that the overall median physicians' adherence to the CAC 
guidelines recommendation for the prescription of lCS for persistent asthma was 
32.9% during the 12-month follow-up period. It may be argued that physicians 
from emergency departments are most likely to refer patients to their family 
physicians for continued care and therefore less likely to prescribe refills with a 
new prescription. lndeed, at treatment initiation, there were fewer patients 
(39.1 %) who had prescribed refills from an emergency department than from an 
outpatient clinic (56.4%) or from a hospita1 (5l.9%). However, the majority of 
initial prescriptions were obtained 'at outpatient clinics (75.7%) and as many as 
43.6% of these patients did not have prescribed refills. 
There are many potential barriers to prescribing lCS that may explain our findings 
including lack of agreement with treatment guidelines recommendations for the 
prescription of daily lCS ta patients with daily symptoms, concerns regarding 
potential side effects of corticosteroids, and family-Ievel barriers such as the cost 
-of the medication which, in our study, is not a barrier since all patients had free 
access to their medications. (13; 14;68) Moreover, a recent Canadian survey 
reported that physicians' assessment of asthma control was not concordant with 
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guidelines assessment ·recommendations, particularly regarding the overuse' of 
SABA which may lead physicians to overestimate control and under prescribe 
lCS.(15) 
Our data suggest that for some patients les may be used only to manage 
exacerbations. lndeed, we found that 20.2%. of children had experienced a 
moderate to severe exacerbation just prior to or on the day of their initial leS 
prescription. During the follow-up period, 27.1 % of children with seven or more 
prescriptions had experienced a moderate to severe exacerbation exc1uding those 
occurring on the day of treatment initiation compared to 21.3% among children 
with two to six prescriptions ~md 13% among children with one prescription. 
When we specifically examined asthma-related events occurring 15 days prior to 
or on the day of a prescription dispensation, for aIl prescriptions (new and refilIs) 
dispensed throughout the 12-month follow-up period, we found that moderate to 
severe exacerbations preceded 14% of leS dispensation. lnterestingly, when 
stratified by prescription status (new and refills), it was found that moderate to 
severe exacerbations preceded 18.1 % of new leS dispensations compared to 2.2% 
of refill dispensations. Since most c1aims throughout the 12-month follow':up 
period were for new prèscriptions (74.3%), these findings again suggest that a 
moderate to severe exacerbation is an important motivator for prescribing or 
obtaining a new prescription of leS. In addition, the lower proportion of refill 
prescriptions (25.7%) dispensed throughout the 12-month follow-up period may 
suggest that les is not used as maintenance therapy. 
We have aiso found that patients had few regular follow-up visits for asthma with 
their physicians which may also explain the un der prescribing of leS. The median 
number of outpatient visits for asthma during the 12-month follow-up period 
including the date of their initial prescription was one which is considered 
suboptimal f~)[ newly-treated asthma patients according to the CAC guidelines. 
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However, the median number of outpatient visits for ail causes was four 
suggesting there may have been sufficient medical encounters to obtain 
prescriptions if the patients or caregivers reportedpoor asthma control. Moreover, 
the median number of different prescribing physicians consulted was two 
indicating that patients have less than optimal continuity of care for the treatment 
of asthma.(121) 
Wh en we examined the physitians' adherence to the CAC guidelines for the re-
evaluation of asthma control and effectiveness of the prescribed maintenance 
therapy, we found that as few as 13.4% and 21.0% of patients had an outpatient 
visits for asthma at 6 weeks and 3 months following treatment initiation, 
respectively. Moreover, only 45.4% patients had an outpatient visits for asthma 
during the 12-month follow-up period following treatment initiation. 
In addition to the suboptimal prescription of ICS by physicians, the overall median 
patient adherence value during the 12-month follow-up period was 58.6% and as 
low as 31.5% among children who had seven or more prescriptions. These results 
are consistent with the adherence rates reported in the literature. (10-12; 122) 
We hypothesize that the lower median adherence rates observed among patients 
with seven or more prescripti~::ms is, among other factors, due to the patients' 
motivation to control their symptoms rather than to prevent symptoms. This 
hypothesis is consistent with the literature which infonns us that asthmatic patients 
often stop prematurely taking their long-term ICS therapy in the absence of 
symptoms or if they have not experienced an attack for an extended period of time. 
(66;102) Patients may also be reluctant to fill long-term ICS prescriptions, 
particularly if they are asymptomatic, because of fear of si de effects. (62; 1 02) 
Poor adherence to prescribed long-term ICS therapy can also be a result of the 
patient's or caregiver's poor perception of the severity of the disease. (99; 123) 
The intermittent nature of asthma may also lead sorne patients to perceive asthma 
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as an acute rather than a chronic disease. (102) Aiso commonly reported, many 
asthmatic patients or their caregivers have a lack of understanding of the role of 
ICS therapy and perceive ICS as symptom relieving rather than preventive. (97) A 
Canadian survey conducted in adults and parents of children aged 4 to 15 years 
reveaied that 48% of patients with poorly controlled asthrua who used an ICS did 
not understand the role of ICS, 45% reported using ICS when having an asthma 
attack and 28% before doing an exercise.(8) 
As anticipated from the literature, the 12 to 15 age group had a Iower overall 
median adherence than the younger age group (52.4% versus 61.5%). (11 ;85;90) 
In addition to the factors influencing adherence described above, it has been 
reported that adolescents may be less prone to take their medication because of 
inconvenience, embarrassment or forgetfulness. (102; 1 03) 
This study also showed that many patients did not attain control of their asthmil by 
the observed frequencies of moderate to severe exacerbations and the continued 
high use of SABA during the follow-up period highlighting the importance of 
treating asthma with maintenance ICS therapy. In fact, only 25% of the patients 
had controlled asthma based on low use of SABA (less than three doses per week 
on average) and absence of moderate to severe exacerbations. We observe that our 
two markers of uncontrolled asthma increases with increased ICS exposure which 
suggests, as described earlier, that the most symptomatic patients are more likely 
to be adherent to their lCS. To explain the high frequencies of markers of 
uncontrolled asthma even in the most adherent patients, we estimated the median 
average daily doses of ICS during the 12-month follow-up period among patients 
with the highest lCS exposure (i.e., > 7 prescriptions of lCS and had an adherence 
50%). The median average daiIy dose was found to be less than 125 fLg. It is 
important to note that a daily dose of'S 200 fLg represents a low aose according to 
the asthma treatment guidelines. Our finding suggests that lCS was not used 
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appropriately even among 'patients with the highest leS exposure to keep asthma 
under control. 
There are several important methodological strengths to our study. We have 
selected patients who would most likely benefit from chronic daily use of leS 
therapy as ail patients had used more than three doses of SABA per week on 
average, a guideline defined marker of poor asthma control, during the one year 
period prior to treatment initiation. We have used a large validated healthcare 
administrative database to assess the use of leS on a population level, which 
provides objective exposure data as it is prospectively collected independently of 
the' physicians and patients and thus, is not subject to interview 'social desirability' 
and recall biases. Another major strength of our study is that we were able to 
identify wh ether the low use of leS was attributable to physicians not prescribing 
les for chronic daily use and/or the patient not filling their prescriptions. The 
Proportion of Prescribed Days eovered (PPDC) adherence measure developed for 
this study is based on a frequently used measure to estimate patient adherence 
from administrative databases, the proportion of days covered (PDC), which is 
defined as the total days' supply dispensed to the number ,of days of study 
participation.(82) Although both the PPDC and PDe measures p\ovide an 
adherence value that represents the proportion of days with medication possession, 
the PDe is most useful when the medication is prescribed for chronic use. In the 
presence of differing prescribing patterns, the PDe may fail to provide information 
about whether the patient is using the medication as prescribed. The adherence 
value provided by the PPDe in our study more accurately represents the patients' 
adherence to the prescribed therapy as it takes into account, in the denominator, 
the quantity of medication prescribed, thereby correctingfor the effect of varying 
prescribing patterns. lndeed, we would have obtained a median adherence value of 
15.1 % had we used the PDe adherence measure instead of 58.6% when using the 
PPDe measure. 
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Our findings must be interpreted in light of sorne limitations. Our study excluded 
patients covered by private drug plans; families with higher income may have been 
underrepresented. However, a previous Canadian study has shown that 
socioeconomic status had little influence on medication prescription patterns for 
thé treatment of asthma in a population of children that had free access to 
prescribed medications. (120) Our findings may not generally apply to 
populations that pay for their medications. Our inability to determine' whether the 
patients' booked and kept follow-up appointments with their physician if indeed 
recommended for reassessment of symptoms and therapy and whether the patients 
receiving a new prescription from their physician have obtained their prescription 
may have resulted in an underestimation of the prescribing patterns as only 
. prescriptions dispensed at the pharmacyare accounted for in the database.(l24) 
Conversely, the prescribing patterns were based on the total number of 
prescriptions a patient could have received from aIl physicians consulted during . 
the 12-month foIlow-up period, which may overestimate the prescribing patterns 
of individual physicians. The adherence value derived from administrative 
databases assumes that patients filled their new prescription and consumed aIl 
medications, thus providing the highest potential adherence. 
A formaI validation of the prescription duration recorded in the RAMQ database 
based on the quantity dispensed and the usual dosage has not beeri. conducted in 
our current study. In addition, it may be possible that the prescription duration 
was underestimatedor overestimated in the event that the prescribed 
recommended use was verbally communicated to the patient and consisted of self 
adjusting the dose until effective control was achieved or reduced to a minimum 
maintenance effective dose. 
We have slightly underestimated the prescribing physicians' adherence to the CAC 
guidelines recommendation for the prescription of ICS and overestimated the 
patierits' adherence to ICS by not accounting for the number of potential renewals 
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corresponding to the 267 prescriptions with a recorded end validation date. 
Ho~ever,based on the results obtained from the two sensitivity analyses, we can 
conclude that our main results for the physicians and patients adherence were 
robust as these estimates were only slightly affected and the conclusion was not 
affected. In the presence of overlapping prescriptions, we did not invalidate the 
perrnitted number of renewals of the previous prescription which may have 
potentially overestimated the physicians' adherence to the CAC guidelines 
recommendation for the prescription of ICS and an underestimated the patient's 
adherence. To minimize the impact of this limitation, the duration of therapy was 
truncated to 365 days to excJude excess medication prescription and medication 
possession. 
Another limitation of the RAMQ database is that it do es not include d~gs 
suppliedin hospitals. We do not believe this could have impacted our findings as 
few patients have been hospitalized and for these patients hospital stays were of 
short duration. Moreover, the diagnosis of asthma in children recorded in the 
RAMQ databases has not been validated; however, it is not anticipated to be 
different than· in adults. What may be questionable is whether the diagnosis of 
asthma was corre~tly attributed in the absence of an objective pulmonary function 
test to confirm the diagnosis. However, by selecting patients who had also used, 
on average, more than 3 doses of SABA per week, during the year preceding 
treatment initiation with ICS, it provides us an additional assurance that our cohort 
reflects patients with persistent asthma. 
OVERALL CONCLUSION 
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Asthma is an increasingly common chronic disorder. It is a lea~ing cause of 
hospitalization in children and brings si"gnificant direct costs to societies. National 
and international guidelines have been developed for the diagnosis, management 
and treatment ofasthma. The pharmacological treatment component of these 
guidelines advocates first-line regular use of leS for patients with persistent 
asthma. This recommendation is based on a wealth of scientific evidence from 
randomized, control\ed clinical trials. [31-36] Regular use of leS has also been 
associated with reduced asthma syrnptoms and severity and is associated with a 
significant lower number of annual emergency and hospitalizations in patients 
with persistent asthma based on 'real world' data from observational studies. [4-6] 
Yet, suboptimal use of leS therapy is common in this population. 
Consistent with the literature, we have foun.d in our study that many physiciansdid 
not prescribed daily leS for their patients with persistent as th ma syrnptoms and 
many of these patients did not use their newly prescribed leS therapy on a daily 
chronic basis, continued to overuse SABA, and experienced moderate to severe 
exacerbations. Differing to lJleasures of refill adherence reported in the literature, 
the measure developed for this study corrected for the prescribing patterns without 
having to consult the patients' medical records, a major benefit in terms of study 
efficiency (i.e., time, inanpower and cost). This is very important in asthma due to 
the presence of varying prescribing patterns to reflect the actual patient adherence 
behaviors. lndeed, in our study, the proportion of the non adherence value 
attributable to the lack of prescribing daily long-term leS therapy was 51.2%. Our 
efforts to disentangle the behaviours of physicians and patients regarding the use 
of leS therapy can be very useful in providing a better understanding of the gap 
between tr~atment goals and asthma control and in the planning of interventions 
aiming at the optimal use of leS therapy. 
It would be interesting to identify, as a next step, the determinants associated with 
the suboptimal prescription of leS as rpaintenance therapy for patients with 
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persistent asthma. Using the same cohort, we cou Id examine differences among 
prescribers and under prescribèrs by characteristics of the physicians such as their 
specialty, age, years since graduation, sex, region of practice, academic affiliation 
and characteristics. of their patient such as age and prior asthma-related risk 
factors. This information could then be used to target individuals for focus groups 
to help elucidate soine of the potential barri ers to prescribing daily long-term leS 
and subsequent tailor interventions to address identified barri ers. 
Despite the widelyavailable treatment guidelines and the positive benefit-risk 
profile of leS therapy, suboptimal asthma control continues to have a major 
impact in children and society. Phys{cians, parents and patients appear to fail to 
recognize that asthma is a chronic.disease and the need to shift focus from treating 
asthma symptoms to using a more preventive approach with regular daily long-
terrn leS therapy. Interventions to encourage disease recognition and widespread 
use of les should continue to be advocated to reduce asthma-related morbidities, 
health care utilization and costs of asthma management. 
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APPENDICES 
Figure 1: Cohort Selection 
New treatment episode with lCS 1 between 1 January 1998 to 
31 December 2004 
No prescription for a leukotriene modifiers and/or long-acting ~2-agonists 
on the day of treatment initiation 
Aged between 5 and 15 years on the day oftreatment initiation 
Enrolled in RAMQ pharmacy insurance plan in the year prior to 
treatment initiation 
Diagnosed with asthma in the year prior to treatment initiation (ICD-9 
code 493) 
No diagnoses of cystic fibrosis (ICD-9 code 277.0) or false croup (ICD-9 
code 478.75) in the year prior to trea~ment initiation 
No prescription dispensation for an acetylcysteine, racemic 
epinephrine, pancrelipase, pancreatine and tobracymine in the year 
prior to treatment initiation 
No OCS dependency (> 182 days) in the year prior to treatment initiation 
Observation period 2: 3 months from treatment initiation 
>3 SABA doses per week on average or 2: 1 asthma-relatedevent 
(an emergency visit, a hospitalization and/or an OCS dispensation) in 
the year prior to treatment initiation 
First treatment episode with lCS 
New prescription (not a refill of a previous prescription) for an lCS on the 
day of treatment initiation 
Observation period of2: 12 months from treatment initiation 
>3 SABA doses per week on average in the year prior to treatment initiation 
XII 
194 128 
193 903 
79835 
65 011 
35664 
35 571 
35475 
35461 
32838 
7849 
7253 
6966 
5836 
2355 
1 New episode defined as the absence of' lCS dispensation in the year prior to 
treatment initiation 
Abbreviations: lCS = lnhaled Corticosteroids. SABA = lnhaled Short Acting ~2-
Agonists. RAMQ = Régie de l'Assurance Maladie du Québec. lCD-9 = 
International Classification of Diseases, 9th Revision. OCS = Oral Corticosteroids 
X III 
Table 1: Location of the prescribing physicians for the initial prescription ofICS 
Number ofpatients 2355 
Location of prescribing physicians l, % 
Outpatient cHnic 
AlI patients 
Patients with no refill 
Patients with > one refills 
Emergency department 
. Ali patients 
Patients with no refill 
Patients with 2: one refills 
Hospital 
AU patients 
Patients with no refill 
Patients with 2: one refills 
Undefined 
AIl patients 
Patients with no refill 
Patients with > one refills 
1 Day of treatment initiation and 15 days prior 
Abbreviation: ICS lnhaled Corticosteroids. 
1102 (75.7) 
480 (43.6) 
622 (56.4) 
299 (20.5) 
182 (60.9) 
117(39.1) 
54 (3.7) 
26 (48.1) 
28 (5 L9) 
900 
434 
466 
Table II: Physicians adherence to the CAC guidelines for the prescription ofICS 
during the 12-month fol1ow-up period 
Number of patients 
Median (95% CI) 
Physicians adherence J 32.9 (28.8-32.9) 
2355 
Percent adherence 
j 
Mean (95% CI) 
39.1 (37.9-40.4) 
XIV 
1 Physicians adherence is defined as the percent days' supply prescribed divided 
by the duration of the study 
Abbreviations: CAC = Canadian Asthma Consensus. ICS lnhaled 
Cortîcosteroids. 
xv 
Table III: Sensitivity analyses for comparison ofphysicians adherence to the CAC 
guidelines for the prescription ofICS and patients adherence to ICS during the 12-
month follow-up period 
Number of patients 
Physicians adherence3 
Median (95% CI) 
Mean (95% CI) 
Main analysis 
2355 
32.9 (28.8-32.9) 
39.1 (37.9-40.4) 
Patients adherence using PPDC 
Median (95% CI) 
Mean (95% CI) 
58.6 (54.8-62.5) 
62.4 (61.1-63.7) 
Sensitivity analysis 11 
2355 
Percent adherence 
34.2 (32.9-37.0) 
43.8 (42.5-45.1) 
50.0 (50.0-50.0) 
57.6 (56.3-58.9) 
Sensitivity analysis 22 
2127 
32.9 (29.6-32.9) 
39.2 (37.9-40.5) 
53.8 (50.0"57.9) 
60.7 (59.3-62.0) 
1 Sensitivity analysis 1 consists of assigning the maximum potential number of renewals 
for the 267 prescriptions with a recorded end validation date. 
Z Sensitivity analysis 2 consists of removing from the analyses the 228 patierits who hadat 
least one prescription with a recorded end validation date. 
3 Physicians adherence is defined as the percent days' supply prescribed divided by the 
duration of the study 
Abbreviations: CAC = Canadian Asthma Consensus. lCS = lnhaled Corticosteroids. 
PPDC = Proportion of Prescribed Days Covered. 
XVI 
Table IV: Physicians adherençe to the CAC guidelines for the re-evaluation of 
asthma control and effectiveness of the prescribed ICS therapy following initiation 
oftherapy 
Number of patients 
Variables 
Number of patients with ~ one outpatient visits for asthma 1 
2355 
Number (%) 
During the first six weeks following treatment initiation 316 (13.4) 
During the first twelve weeks following treatment initiation 494 (21.0) 
1 lncluding outpatient visits to all physicians a patient could have consulted. 
Abbreviations: CAC = Canadian Asthma Consensus. ICS =lnhaled 
Corticosteroids. 
XVll 
Table V: Comparison of patient adherence rates to ICS using two adherence 
measures (PPDC and PDC) during the 12-month follow-up period 
Number ofpatients 2355 
Variables 
Patient adherertce using PPDC 
Patient adherence using PDC 
Percent adherence 
Median (95% CI) 
58.6 (54.8-62.5) 
15.1 (13.7-15.1) 
Mean (95% CI) 
62.4 (61.1-63.7) 
18.5 (17.9-19.1) 
Abbreviations: lCS = InhaJed Corticosteroids. PPDC = Proportion of Prescribed 
Days Covered. PDC = Proportion ofDays Covered. 
XVlll 
Table VI: Patient adherence to ICS using the PPDC measure for all patients and 
per age groups (5-11 years and 12-15 years) during the 12-month follow-up period 
Variables Percent adherence 
Patients 5-15 years old (N=2355) 
All patients 
Patients with 
2-6 prescriptions 
?:.7 prescriptions 
Patients 5-11 years old (N=1584) 
All patients 
Patients with 
2-6 prescriptions 
?:. 7 prescriptions 
Patients 12-15 years old (N=771) 
. All patients 
Patients with 
2-6 prescriptions 
?:.7 prescriptions 
Median (95% CI) Mean (95% CI) 
58.6 (54.8-62.5) 
55.8 (50.7-60.0) 
31.5 (28.9-33.9) 
61.5 (57.1-66.7) 
60.0 (54.8-65.0) 
32.9 (29.9-35.6) 
52.4 (50.0-60.0) 
50.0 (50.0-54.8) 
28.9 (27.4-33.0) 
62.4 (61.1-63.7) 
60.9 (59.3-62.5) 
36.8 (35.1-38.6) 
62.4 (61.1-63.7) 
60.9 (59.3-62.5) 
36.8 (35.1-38.6) 
60.0 (57.7-62.3) 
57.0 (54.1-59.9) 
36.4 (33.4-39.4) 
Abbreviations: ICS = lnhaled Corticosteroids. PPDC = Proportion of Prescribed 
Days Covered. 
XIX 
Table VII: Asthma-related events occurring 15 days prior to or on the day of an 
ICS dispensation throughout the 12-month follow-up period 
Variables Number (%) of prescriptions dispensed 
Type of prescriptions 
N umber of prescriptions 
dispensed 
Dispensed oral corticosteroids 
Visits to an emergency 
department for asthma 
Hospitalizations for asthrna 
Moderate t6 severe 
Ali prescriptions 
(new and refills) 
5425 (100) 
511 (9.4) 
563 (10.4) 
91 (1.7) 
New 
prescriptions 
4030 (74.3) 
489 (12.1) 
541 (13.4) . 
85 (2.1) 
Refill 
prescriptions 
1395 (25.7) 
22 (1.6) 
22 (1.6) 
6 (0.4) 
exacerbations l 759 (14.0) 729 (18.1) 30 (2.2) 
1 Moderate to severe exacerbations is defined as a composite outcome of a 
dispensed prescription for a short course OCS (14 days or less), an asthma-related 
emergency department visit or an asthma-related hospitalization. 
Abbreviations: ICS = Inhaled Corticosteroids. OCS = Oral Corticosteroids. 
xx 
Table VIII: Number of patients with controlled asthma during the 12-month follow-up period 
Use ofICS 
Total number of prescriptions 2-6 ?7 
Patient adherence, % 100% <50% ?50% <50% ?50% 
Number of patients 468 469 801 475 142 
Number of patients with 
controlled asthma l , (%) 23'5 (50.9) 145 (30.9) 133 (16.6) 68 (14.3) 6(4.2) 
10_3 doses of SABA per week on average and absence of a moderate to severe exacerbation 
defined as a composite outcome of a dispensed prescription for a short course OCS (14 days 
or less), an asthma-related emergency department visitor an asthma-related hospitalization. 
Abbreviations: SABA = Inhaled Short Acting ~2-Agonists. OCS = Oral Corticosteroids 
xxi 
Table IX: Examples of refill adherence assessment measures 
Measure Formula Value 
CSA Total days' supply dispensedltotal Adherence value per single refill 
days' in interval interval 
CSG Total days' treatment gaps /total Non adherence value per single refill. 
days' in interval interval 
CMA Total days' supply dispensedltotal Adherence value for cumulative period 
days' over a series of intervals of interest l 
CMG Total days' treatment gaps/total Non adherence value for cumulative 
days' over a series of intervals period of interest 1 
CR [(Total days' supply dispensed- Adherence percentage for period 
days' supply of last between first and la st refitl 
dispensation)/total days' between 
first and last dispensation] X 100 
MPR Total days' supply dispensedltotal Ratio of medication availability 
days' study participation per 
participant 
MRA [Total days' supply Overall adherence percentage 
dispensedltotal days' study 
participation] X 100 
PDC [Total days' supply Overall adherence percentage 
dispensedltotal days' study 
participation] X 100, capped at 
one 
1 The end date may be the last fJll or an arbltrary date such as the end of the calendar year 
or the end of the observation period. 
Abbreviations: CMA = continuous, multiple-interval measure of medication availability 
(or acquisition). CMG = continuous, multiple-interval measures of medication gaps. CSA 
= continuous, single-interval measure of medication availability (or acquisition). CSG = 
continuous, single-interval measure of medication gaps. CR = compliance rate. MPR = 
medication possession ratio. MRA = medication refill adherence. PDC = proportion of 
days covered. 
Adapted from Hess et al 2006 and Steiner et al t 997 
